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1.1 Equal versus Response-Adaptive Randomization
Two considerations are paramount when designing a clinical trial. First is to ensure that the trial
is sufficiently powerful to detect some clinically-meaningful difference between treatment groups,
should one exist; while second is ensuring that the trial adheres to the ethical principles of research
with human subjects set forth by the Belmont Report. [1,2] However, consider a phase III randomized
clinical trial (RCT) where evidence exists suggesting that a novel treatment is superior to a current
method of treatment (i.e., an active-control). In such a scenario, the power-versus-ethics dynamic
of the RCT may be at-odds, a situation that will be discussed at length throughout the present
work.
Equal randomization (ER) occurs when an equal number of trial participants are randomized
to each study arm. In addition to being the most implement and conceptually-straightforward
method of randomization in RCTs, ER is also the most powerful method of randomization when
the responses obtained from each arm of the RCT vary equally. Therefore, implementing ER may
save both time and money throughout the duration of the trial because a clinically-meaningful
difference can be detected using response information obtained from fewer participants than would
be required under any other type of randomization. [1] Equal randomization may be unethical if a
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treatment difference exists despite its power and ease of implementation. Returning to the context
of the phase III RCT where a novel treatment has shown evidence of outperforming a standard-
of-care treatment, by definition, half of all trial participants will be randomized to the inferior
active-control group.
In this instance, two ethical principles of research with human subjects are being violated. First
is the principle of beneficence, or the “do no harm” principle which seeks to maximize the benefit and
minimize the risk to human subjects. [2] Beneficence dictates that human subjects should undergo
the most superior treatment available for their ailment. To allocate any subject to an inferior
treatment could be considered harmful in that it is not acting in the subject’s best interest: the
subject is not benefiting from the best treatment available and may be experiencing a greater risk
of experiencing poorer health outcomes as a result. The second principle of research with human
subjects that may be violated is the justice principle which calls for the equitable treatment of and
access to resources for every human subject. [2] Using similar logic, to deny any subject access to
a superior treatment may be considered unjust treatment in that available resources that could
benefit the subject are being withheld.
A more ethical randomization mechanism is one that, in the presence of a treatment difference,
apportions subjects to competing treatment arms in such a way that power is maintained and the
greatest number of subjects possible receives the most beneficial treatment. [3] Such a randomization
method is called response-adaptive randomization (RAR). Response-adaptive randomization is a
sequentially-updating process in which the treatment responses from participants who have com-
pleted the trial are used to influence randomization for incoming subjects such that randomization
tends toward the better-performing treatment group, should one exist. [3–7] Existing RAR designs
can be grouped into two broad categories: non-optimal (§1.2) and optimal designs (§1.3). Optimal
RAR mechanisms strike a balance between randomization according to ethical and statistical pow-
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er, while non-optimal RAR designs target ethical randomization. While optimal RAR is the focus
of the present work, a brief description of non-optimal designs are provided in what follows.
1.2 Non-optimal Response-Adaptive Randomization Designs
There are a number of non-optimal RAR designs. Some randomize subjects according to a distribu-
tional link function (described in Appendix A.1), while others are adapted from methods originally
purposed for binary response data or are based on nonparametric score functions. Examples of the
former include the Doubly-adaptive Biased Coin Design [1,3,8–10] (DBCD), the Continuous Drop-
the-Loser (CDL) design [11,12], and the Randomized Play-the-Winner (RPW) design [13]. A brief
overview of these methods is available in Appendix A.2, and the DBCD as it relates to RAR is
discussed later in this chapter.
Nonparametric scores can also be used to construct RAR designs for continuous and time-
to-event response data. Rosenberger [14] developed nonparametric RAR designs for continuous
data using treatment effect mapping (TEM), while Rosenberger and Seshaiyer [15] and Hallstrom
et al. [16] used TEM for time-to-event response data. Bandyopadhyay and Biswas [17] developed
the Wilcoxon-Mann-Whitney adaptive design (WAD) using components from both the Wilcoxon-
Mann-Whitney (WMW) test [17–19] and the Friedman-Wei (FW) urn design [20–22]. Treatment effect
mapping designs and WAD are described in more detail in Appendices A.3 and A.4, respectively.
1.3 Optimal Response-Adaptive Randomization Designs for Continuous Re-
sponse Data
Non-optimal RAR designs target ethical randomization. Trials focused purely on the ethical aspect
could allocate nearly all subjects to the superior treatment without regard for the necessary accrual
of subjects in each treatment group to maintain an adequate level of power to detect a treatment
difference. Thus, the determination of treatment superiority would be impossible. Optimal RAR,
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on the other hand, optimizes an objective function based upon an importance criterion subject
to a variance constraint. [4–7] An importance criterion is the primary ethical concern of the trial,
such as minimizing the expected number of treatment failures, the total expected sample size, the
total expected cost, or the expected number of subjects allocated to the inferior treatment. This
importance criterion is translated into an objective function governed by the treatment-specific
sample sizes and the moments of some assumed response distribution. A variance constraint is
imposed upon the ethical concern represented by the objective function such that a larger number
of subjects will receive the superior treatment when a treatment difference exists while also ensuring
that the number of subjects necessary to maintain power will undergo the inferior treatment. If
no treatment difference exists, the variance constraint ensures ER is maintained. The variance
constraint is established by setting-equal a constant and the asymptotic variance of the estimated
treatment difference, where the variance constraint is focused on the variance related to the statistic
used to test the study hypothesis. Optimization occurs when the objective function is subject to
the variance constraint, producing an optimization problem which returns the powerful and ethical
optimal randomization ratio. Optimization details are provided in Appendix A.5 and will be
referenced throughout the present work.
Jennison and Turnbill [23] and Biswas and Mandal [5] developed early iterations of optimal RAR
designs; each of these are described with greater detail in Appendices A.6 and A.7, respectively.
From these, Zhang and Rosenberger [6] developed an optimal RAR design. In this design, assume
two groups, a treatment T and an active control C, where groups are denoted by g, i.e., g ∈ {T,C},
and group-specific responses have a mean µg and variance σ
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unknown and smaller responses are more desirable. Then, this design minimizes the total expected
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nT µT + nC µC
}
, (1.1)
where E[·] is the expectation function. Solving this according to the asymptotic variance of the
estimated treatment difference,






= V, for some constant V, (1.2)
where ng is the number of subjects allocated to treatment g and setting V equal to one, as suggested











A noted criticism of this design is that it degenerates if either of the group-specific response
mean estimates, µ̂T or µ̂C , are negative.
[3,6] Otherwise, this design can be applied whenever response
values are known to be positive. One proposed solution for negative responses is to add a sufficiently
large positive constant, ypos ∈ R+, such that all responses are positive-valued. [3,6] Then, Zhang

















as ypos tends toward infinity. Neyman-Pearson randomization is optimal, but not ethical. Therefore,
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for responses taking negative values, Atkinson and Biswas [3] suggested assuming a distribution left-
truncated at zero. Such a distribution is defined as P (X = x) = f(x) for x ≥ 0, 0 otherwise, where
f(x) is the density function of a random variable X.
Nevertheless, the Zhang and Rosenberger [6] randomization rule can be applied whenever re-
sponse values are known to be positive. One such example is when responses are assumed to be
exponentially-distributed, i.e., Yg ∼ Exp(θg), where the expected group-specific response is given




nT θT + nC θC
}
, (1.6)
and, since V ar(Yg) = θ
2
g , the variance constraint of (1.2) takes the form:






= V, for some constant V. (1.7)
Per this optimal RAR framework, solving (1.6) subject to (1.7) gives the following optimal RAR








Similar results can be obtained when response values followed gamma distributions, i.e., Yg ∼
Gam(αg, βg), as well. The expected group-specific response is given by E(Yg) = αgβg; therefore,




nT αTβT + nC αCβC
}
; (1.9)
and, since V ar(Yg) = αgβ
2
g , the variance constraint is given by:










= V, for some constant V. (1.10)










1.3.1 Tuning Based on Treatment Effect
Biswas and Bhattacharya [7] capitalized on the applicability of the Zhang and Rosenberger [6] design
to any positive real-valued continuous response distribution in order to create an optimal RAR
framework. [4,6,7] Introduced into this design are:
1. Ψ, a general representation of the function of the moments comprising the objective function,
2. ρ0 ∈ (0, 1), a prespecified target randomization probability for a given effect size,
3. τ ≥ 0, a tuning parameter used to achieve ρ0 when a desired treatment difference is observed,
4. Additional constraints based on ng/(nT +nC) ≥ b intended to bound the randomization ratio
between b and 1− b, where b ∈ [0, 1/2) and small.
Biswas and Bhattacharya [4] applied these modifications to the Zhang and Rosenberger design.





nT Ψ(µT ) + nC Ψ(µC)
}
. (1.12)











The choice of Ψ(·) is objective-specific based upon the desired importance criterion. [7] Where the
goal of Zhang and Rosenberger’s design [6] was to minimize the total expected mean response, Biswas
and Bhattacharya [4] suggested using Ψ(x) = xτ . The desired randomization ratio, ρ0, is defined
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This value, τ , permits the integration and attainment of a predetermined target randomization
proportion within the randomization procedure itself. This ensures that the randomization propor-
tion occurs at approximately the same rate for a given treatment difference regardless of the scale
of the outcome measure.
Subjecting (1.12) to (1.2) using the Biswas and Bhattacharya’s [4] Ψ(x) = xτ generalization of












and bounded as follows:
ρ =

b, if {Ψ(µT ) > 0 and Ψ(µC) > 0 and ρ′ < b}
ρ, if {Ψ(µT ) > 0 and Ψ(µC) > 0 and b ≤ ρ′ ≤ 1− b}
1− b, if {Ψ(µT ) > 0 and Ψ(µC) > 0 and ρ′ > 1− b}
b, if {Ψ(µT ) > 0 and Ψ(µC) < 0}
1− b, if {Ψ(µT ) < 0 and Ψ(µC) > 0}










where ρ represents the probability that a subject is randomized to treatment group T . Because the
Biswas and Bhattacharya [7] optimal RAR design provides a general framework for the optimal RAR
process, is bounded between b and 1− b, and allows randomization to target a desired proportion
which is achieved when a desired treatment difference is observed, this framework is the one used
in the present work for continuous response data.
1.4 Motivation: The Problem of Misspecification
For most types of statistical analyses, data are typically assessed for some distributional assump-
tion prior to statistical analysis as a safeguard against erroneous statistical conclusions. This is
not the case for response-adaptive RCTs. Recalling Section 1.1, when planning a RCT, an inves-
tigator must know the number of subjects that will be enrolled into the trial in order to detect
a clinically-meaningful difference between treatment groups. Typically, in the context of RCTs
with continuous response data, this value is determined by assuming subject responses will follow
a normal distribution. Section 1.3 described how optimal RAR is dictated by the moments of the
assumed response distribution. Therefore, for RCTs employing optimal RAR, it is ideal that the
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observed response data match the assumed distribution. If the observed responses do not follow the
intended distribution, the randomization mechanism may be misspecified. Consequently, partici-
pant randomization may differ from what was intended, possibly producing study characteristics
(i.e., ethics and power) dissimilar from those originally anticipated. These effects may be more
profound in smaller samples and scenarios where the intended response distribution is symmetric
yet observed response data are skewed or vice versa. Though means tend to be robust against
distributional misspecification, treatment group variance estimation is heavily contingent upon the
correct specification of the assumed distribution. [24]
1.4.1 The Biasedness Dilemma
Consider the randomization ratio of (1.17). Assume that ρ′ is already bounded and is, therefore,
ρ. As discussed in Section 1.3, (1.17) is a function of some unknown group-specific population
parameters µg and σ
2
g . However, pursuant to the optimal RAR process,
[4–7] randomization is dic-
tated by the observed response information obtained from subjects who have already completed the
trial. Therefore, the observed optimal RAR ratio for continuous response data is calculated using
the estimated treatment-specific mean and variance of the response data obtained from subjects
{1, 2, · · · , i}, denoted µ̂gi and σ̂2gi, respectively. Therefore, the RAR ratio for participant i+ 1 to T











By Jensen’s Inequality, [24] replacing the distributional parameters with sample estimates could
result in a biased estimate of the randomization ratio. Despite this, plug-in estimators, specifically
maximum likelihood estimators (MLEs), are convention and, therefore, are used in the present
work.
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1.4.2 Objective and Outline of Present Work
There exists a paucity of information regarding the trial ramifications that may occur if the distri-
butional assumption of the participant response data is not met. That is, existing literature falls
short of addressing the behavior of the derived methodologies in the presence of distributional mis-
specification of the observed response data, a conceivable possibility given the assumed distribution
is chosen prior to data collection. [4–7,23] This is an important consideration given randomization of
incoming participants is contingent upon the response data obtained to that point, and the estima-
tion of the mean and variance used to estimate the RAR ratio is effected by the specification of the
response data. Traditionally, the DBCD is employed to account for unintended trial characteristics
resulting from a small sample size, e.g., large variance. [8–10] This procedure operates as a function
of the optimal RAR ratio, and therefore is not, in itself, optimal. The DBCD dampens the effect of
the power-versus-ethics dynamic of the optimal RAR framework, no longer randomizing subjects
based on the observed effect size. Of interest in the present work, however, is to study the effects
of misspecification on optimal RAR. Therefore, the DBCD was not used.
The present work sought to identify flexible methodologies that produced an estimator of the
optimal RAR ratio that was robust against departures from a prespecified parametric response dis-
tribution. To this end, nonparametric methods were first used to estimate the empirical distribution
of the observed response data in order to obtain distribution-free estimates of the group-specific
sample moments (Chapter 2). These were, in turn, used to develop an estimator of the RAR
ratio that is robust to distributional misspecification. A step further was the utilization of the
weighted-average approach, a method that allowed the randomization ratio to adjust automatically
according to the distributional fit of a set of parametric candidate response distributions, regardless
of the a priori distributional assumption (Chapter 3). Chapters 2 and 3 detail these approaches
in the context of continuous response data. Chapter 4 centers about right-censored survival out-
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comes, evaluating the misspecification of the conventional Zhang and Rosenberger [25] RAR ratio
and developing a RAR ratio using the cumulative hazard function. The final chapter (Chapter 5)
discusses implications, limitations, and future work.
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Chapter 2
Robust Estimation of Continuous Moments Using the
Empirical Distribution Function
2.1 Distribution-independent Estimation of Moments
The goal of the present chapter is to obtain distribution-independent estimates of the group-specific
means and SDs of the observed response data. These estimates, in turn, are used to produce an
estimate of the RAR ratio that is robust against distributional misspecification. Distribution-
independent moment estimates can be obtained using the cumulative distribution function [26–29]




(1− F (y))dy, (2.1)
E(Y 2) = 2
∫ ∞
0
y(1− F (y))dy, (2.2)
Then, V ar(Y ) = E(Y 2)− E(Y )2, (2.3)
and, SD(Y ) = V ar(Y )1/2, (2.4)
where (2.1) and (2.2) are derived in Muldowney et al. [29] The CDF lacks an easily-estimable closed-
form solution for observed response data that are not assumed to follow a parametric distribu-
tion. [26–28] Therefore, obtaining distribution-independent moment estimates requires an empirical
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estimate of the CDF (eCDF). [26–29] The eCDF can be estimated by sorting the observed response
data into ascending sequence and setting the mass of each observed response value at a height equal
to the number of responses less than or equal to that response value, divided by the total number
of observed responses. While this is a simple and effective approach for obtaining the underlying
distribution function, the resulting data-generating function is a step function modeling a discrete
random variable. Therefore, because the focus of this work is on continuous response data, the
relationship between the survival function [26–28] (SF), S(y), and the CDF,
F (y) = 1− S(y), (2.5)
was exploited. With this, continuous fits of the empirical distribution function, denoted F̂ (y), could
be obtained such that distribution-independent estimates of the means and SDs could be estimated
from the observed response data directly. A number of methodologies have been developed to
estimate the SF, [30–32] but piecewise-linear estimation of the Kaplan-Meier (KM) estimate of the SF
(PLKM) by Kaczynski et al. [33] and Hazard Estimation with Flexible Tails (HEFT) by Kooperberg
et al. [34] were utilized in the present work. The PLKM and HEFT methods were selected for their
simplicity and complexity, respectively, and are detailed in Sections 2.1.1 and 2.1.2, respectively.
Once these empirical SF modeling approaches yielded F̂ (y), group-specific distribution-independent




(1− F̂ (yg))dyg, (2.6)
Ê(Y 2g ) = 2
∫ ∞
0
yg(1− F̂ (yg))dyg, (2.7)
Then, ̂V ar(Yg) = Ê(Y 2g )− Ê(Yg)2, (2.8)
and, ŜD(Yg) = ̂V ar(Yg)1/2. (2.9)
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Plugging these empirical moment estimates into the equation for the RAR ratio given by (1.18)
produces a robust estimator of the RAR ratio.
2.1.1 Piecewise-linear Estimation of the Kaplan-Meier Estimate of the Survival Func-
tion
Mentioned previously, methods of estimating the SF were exploited so that continuous distribution
functions could be obtained from the observed response data. The first method selected for this task
relied upon one of the most common and straightforward estimators of the SF: the KM estimator,
denoted SKM (y).
[31–33] For survival outcomes, SKM (y) may be interpreted as the probability of
surviving until immediately prior to a given time y.i In the absence of censoring, however, SKM (y)
is simply the complement of the previously-detailed eCDF. [32]
2.1.1.1 Fitting PLKM
Letting j index a set of K observed subject responses, denoted y(j) (j = 1, 2, · · · ,K), ordered such
that y(1) < y(2) < · · · < y(K), where y(j) denotes the jth ordered value in the set of K observed
responses, the KM probability of survival corresponding to each observed response value are se-
quenced in descending order, SKM (y(1)) > SKM (y(2)) > · · · > SKM (y(K)), generating a decreasing
step function. In order to obtain a continuous estimate of SKM (y), information between each ob-
served response value (i.e., each downward step) was interpolated using a series of piecewise-linear
functions. [33] To this end, knot points were placed at each observed response value at heights given
by h(j) =
K−j
K−1 , such that h(1) = 1 > h(2) > · · · > h(K−1) > h(K) = 0, and were connected using
line segments with slope
h(j)−h(j+1)
y(j)−y(j+1)
for j = 1, 2, · · · ,K − 1. This concatenation of line segments
produced ŜP (y), a continuous piecewise-linear approximation of the discrete KM estimate of the
SF.
iy, versus more conventional t notation, used to represent survival time (1) to ensure consistent representation
of observed response data, and (2) because present methods, though typically discussed in a survival context, are
centered about continuous response data in this chapter.
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2.1.1.2 Moment Estimation Using PLKM Fit
Using ŜP (y), distribution-independent moments were estimated using numerical integration by the
trapezoidal rule. [35] Specifically, Ê(Y )P was found by summing the area of the trapezoids bounded
on the right and the left by y(j+1) and y(j), respectively, and above and below by Ŝ
P (y) and 0,













where ∆yj = (y(j+1) − y(j)). Next, to obtain Ê(Y 2)P , ŜP2 (y), a piecewise-linear curve representing
the height of each knot point multiplied by the observed response value corresponding to the
location of that knot point, i.e.,
ŜP2 (y) = h(j) × y(j), (2.12)
was calculated. With this, Ê(Y 2)P was calculated by summing the same trapezoids used to calculate
Ê(Y )P , except bounded above by ŜP2 (y) instead of Ŝ
P (y). Building upon (2.7),








h(j) × y(j) + h(j+1) × y(j+1)
)
∆yj . (2.14)
The distribution-independent estimate of the variance follows directly from (2.8) and ŜD(Y )P






gives the robust RAR estimator obtained using the PLKM empirical
estimation method.
iiGroup affiliation dropped for remainder of PLKM moment derivations for ease of notation and without loss of
generality.
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2.1.2 Hazard Estimation with Flexible Tails
The second method for obtaining a continuous distribution function from the observed response
data was HEFT estimation, a more sophisticated and procedurally-complex estimation method
than PLKM. [34,36] Hansen et al. states that, in survival analysis, the hazard function, λ(y)dy, “is
often of-interest since it can be interpreted as the probability that someone dies in the next time-
interval of infinitesimal length dy, given he is alive at time y.” [36] Attempting to model the hazard
function directly can be problematic, however. [31,32,34,36,37] Therefore, Kooperberg et al. [34,37] and
Hansen et al. [36] suggested modeling the logarithm of the unknown hazard function (i.e., log-hazard
function) instead. Compared to the hazard, density, or distribution function, positivity constraints
are not a concern when modeling the log-hazard function, and such an approach lends itself well
to Cox proportional hazards modeling. Described in the following section, the HEFT estimation
method uses cubic splines to model the log-hazard function in a way that allows for and captures
a wide range of tail behavior.
Polynomial splines are piecewise polynomials of some degree d, and knots mark the breakpoints
from one polynomial to the next. [34,36] Splines satisfy smoothness constraints that describe how
the different pieces are to be joined, typically in terms of s, the number of continuous derivatives
exhibited by the piecewise polynomials. Specifically, cubic splines are piecewise cubic functions
having two continuous derivatives, allowing jumps in the third derivative at the knots. Given a
degree d and a knot vector y = (y1, y2, · · · , yK)′, the collection of polynomial splines having s
continuous derivatives forms a linear space. The collection of linear splines with knot sequence y
is spanned by the functions:
1, x, (x− y1)+, · · · , (x− yK)+, (2.15)
where (·)+ = max(·, 0). This is the truncated power basis. In the case of the cubic spline, where
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d = 3 and s = 2, the basis, B(y), is spanned by:
1, x, x2, x3, (x− y1)3+, · · · , (x− yK)3+. (2.16)
Technical details regarding polynomial spline modeling are available in Chapter 2 of Hansen et
al. [36]
2.1.2.1 Fitting HEFT
Let f be a positive density function on (0,∞), ϕ = log(f) be the log-density function, λ = f/(1−F )
be the hazard function, α = log(λ) be the log-hazard function, and, Q = F−1 be the quantile
function such that Q(F (y)) = y for y > 0 and F (Q(p)) = p for 0 < p < 1. Then, for y ≥ 0,
















And, since (i) F (y) < 1 for 0 < y <∞ and (ii) limy → ∞ F (y) = 1, it was concluded that
∫ y
0
exp(α(u))du <∞ for 0 < y <∞, and (2.19)∫ ∞
0
exp(α(y))dy =∞. (2.20)
Noting λ = exp(α), for y > 0,












Now, in an arrangement similar to that of the PLKM method, consider K ≥ 3 observed respons-
es given by y(j) (j = 1, 2, · · · ,K) such that 0 < y(1) < y(2) < · · · < y(K) < ∞, and let p = K − 2.
As well, let G be a p-dimensional space of twice-continuously differentiable functions s on [0,∞)
such that s is constant on [0, y(1)] and [y(K),∞), and the restriction of s to each of the intervals
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[y(1), y(2)], · · · , [y(K−1), y(K)] is a cubic polynomial. With this, the functions in G are cubic splines
having simple knots at y(1), y(2), · · · , y(K). Now, let B1(y), B2(y), · · · , Bp(y) be a basis of this space
such that Bp(y) = 1 on [0,∞) and B1(y), B2(y), · · · , Bp−1(y) = 0 on [y(K),∞). Take ε to be the






and B0(y) = log(y + ε), for y > 0. (2.23)
Kooperberg et al. [34] and Hansen et al. [36] provide details motivating the inclusion of these addi-
tional log terms. Then, B−1(y), B0(y), B1(y), · · · , Bp(y) is a basis of the linear space spanned by
G ∪ {B−1, B0} such that:
α(·|θ) = θ−1B−1(y) + θ0B0(y) + θ1B1(y) + · · ·+ θpBp(y), (2.24)
θ = (θ−1, θ0, θ1, · · · , θp)′ ∈ RK , and (2.25)
Θ =
{
θ ∈ RK :
∫ y
0








θ = (θ−1, θ0, θ1, · · · , θp)′ ∈ RK : θ−1 > −1 and θ0 ≥ −1
}
. (2.27)
With this, α(·|θ), θ ∈ Θ, is the log-hazard function fit to the observed response data using
cubic spline modeling per the HEFT method. Additionally, given basis coefficients θ ∈ Θ,
the corresponding hazard, density, log-density, and survival functions are, respectively, given by
λ(·|θ) = exp(α(·|θ)), and, for y > 0,





















2.1.2.2 Moment Estimation Using HEFT Fit
The aforedescribed modeling of α(·|θ) and 1 − F (y|θ) was performed in R using the polspline
package, where α(·|θ) was obtained using the polspline::heft function and F (y|θ) was obtained
using the polspline::pheft function. [38,39] Denoting ŜH(y) = 1 − F (y|θ), once more, numerical
integration by the trapezoidal rule was used to obtain the distribution-independent mean, Ê(Y )H ,
and SD, ŜD(Y )H . That is, Ê(Y )H , ŜH2 (y), and Ê(Y
2)H were obtained using (2.11), (2.12), and
(2.14), respectively, but with a single change. Where the PLKM method inherently produced K−1
trapezoids for numerical integration across the j = 1, 2, · · · ,K ordered subject responses, the HEFT
method produces a smooth fit of the SF. Therefore, the minimum and maximum observed response
values, y(1) and y(K), respectively, were obtained, and K = 1, 000 equally-spaced intervals were
used to produce K − 1 = 999 trapezoids of equal width between y(1) and y(K). Letting the left-
hand side of a given trapezoid be j and the right-hand side be j + 1, the top of the trapezoid was
given by the line segment connecting h(j) = Ŝ
H(y(j)) and h(j+1) = Ŝ
H(y(j+1)) (or h(j) = Ŝ
H
2 (y(j))
and h(j+1) = Ŝ
H
2 (y(j+1)) for second moment estimation). With this, (2.11), (2.12), and (2.14) was
applied, and Ê(Ygi)
H and ̂SD(Ygi)H were supplanted into (1.18) to produce the HEFT-derived
robust RAR ratio estimator ρ̂HT ;i+1.
2.2 Methods Evaluation and Simulation Process
A simulation study was performed to determine how well the PLKM and HEFT methods account-
ed for the distributional misspecification of the RAR ratio. The goal of this simulation study was
to assess the bias, precision, and ethicality of the RAR ratios obtained using each of the empir-
ical methods of moment estimation. Bias and precision were evaluated to gauge how well the
distribution-independent empirical estimation methods response-adaptively randomized subjects
into a trial when observed responses followed a parametric continuous distribution. The means
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and 95% confidence intervals (CI) of the RAR ratios comprised of moments estimated using either
the PLKM or HEFT empirical estimation methods averaged over 1,000 simulated trials, denoted
ρ̂P and ρ̂H, respectively, were plotted with respect to both the means and 95% CIs of the RAR
ratios estimated using the MLEs of the correctly-specified, true response distribution, denoted ρ̂T,
and the RAR ratio intended by the trial design, denoted ρd. Means of the 1,000 simulated trials
were plotted to measure bias, where smaller distances from the empirically-estimated ρ̂P or ρ̂H to
ρ̂T or ρd represented less bias, and, thereby, greater accuracy of the empirical methods. Ninety-
five percent CIs about the mean RAR ratios were provided as a measure of the precision of these
estimators.
Plots of the percent-difference between the observed and expected ethical objective function
(%O-E) were used to evaluate whether or not the empirical estimators of the RAR ratio randomized
participants into the trial in a manner consistent with the ethical objective of RAR. If RAR adhered
to the intended ethical objective, the observed ethical objective function should have matched the
ethical objective function intended by the trial design. Therefore, estimators of the RAR ratio with
%O-E closer to zero were considered better behaved and, thereby, better performing in this context.
Details for the calculation of the %O-E metric are provided later in this section. Finally, type I error,
i.e., detecting a treatment difference when one does not exist, was evaluated using an independent
samples t-test based on the observed responses from the first 100 participants enrolled into the
simulated trials where no treatment effect was generated (i.e., δ = 0.0, described subsequently).
Figure 2.1 provides a visual representation of the complete simulation process. In these simu-
lations, group-specific participant response data were generated to follow four parametric response
distributions: two exponential family distributions, the symmetrical normal distribution and the
right-skewed gamma distribution, and two non-exponential family mixture distributions, the heav-
ily right-skewed χ2-Uniform (X2U) mixture distribution with a long, thick tail and a bimodal
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Figure 2.1: Simulation process for evaluation of empirical estimation methods using parametric
continuous response data.
mixture of two normal random variables, i.e., the Normal-Mixture (NM) distribution. Algorithms
describing trial generation and participant randomization as well as the simulation of X2U and NM
response data are provided in Appendices A.8-A.10, respectively. These distributions were selected
to show the behavior of RAR in increasingly complex settings. Group-specific means and SDs were
obtained by estimating the MLEs of the parameters that characterize each response distribution.
Derivation of the normal, gamma, X2U, and NM distribution MLEs, along with their means and
SDs, are provided in Appendices A.11-A.14, respectively. These MLE-derived means and SDs were
supplanted into the RAR ratio given by (1.18) in Section 1.4.1 to produce distribution-specific
estimators of the RAR ratio.
Four treatment differences, or effect sizes, denoted δ, were considered in this simulation process.
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These treatment differences were calculated using Cohens D assuming a pooled SD:
δ =
µC0 − µT0√
(1− ρ0) σ2C0 + ρ0 σ2T0
, (2.31)
where ρ0 was used as a proxy for the group-specific sample sizes.
[40,41] With this, group-specific
response data reflecting no (δ = 0.0), small (δ = 0.2), moderate (δ = 0.5), and large (δ = 0.8)
treatment differences were generated. [40,41] The aforementioned evaluation of type I error was in-
corporated into the scenarios where no treatment difference existed (δ = 0.0).
Table 2.1: Distribution-specific parameter values for simulation of treatment
and control group response data by effect size.
Parameter values fixed across effect sizes
Truth Type Value τ for ρ0 = 0.75
Normal Scale/SD, σ0 8.00 33.22
Gamma Shape, α0 4.00 7.89
X2U Mixture, π0 0.50 2.38
Uniform lower bound, a0 0.50
Uniform upper bound, b0 50.50
NM Mixture, π0 0.50 17.99
1st & 2nd Nrv SD, σ1,g0 & σ2,g0 15.00
Overall SD, σ0 38.08
Parameter values varied by effect size
Control/None Small Moderate Large
Truth Type δ = 0.0 δ = 0.2 δ = 0.5 δ = 0.8
Normal Location/Mean, µg0 100.00 98.40 96.00 93.60
Intended RAR ratio, ρd 0.50 0.57 0.66 0.75
Gamma Scale, βg0 2.50 2.27 1.97 1.72
Mean, µg0 10.00 6.89 7.88 9.07
SD, σg0 5.00 4.53 3.94 3.44
Intended RAR ratio, ρd 0.50 0.57 0.67 0.75
X2U X2 DF, kg0 25.00 20.43 12.73 1.12
Overall mean, µg0 25.25 22.96 19.11 13.31
Overall SD, σg0 11.37 11.45 12.56 15.93
Intended RAR ratio, ρd 0.50 0.53 0.61 0.75
NM 1st Nrv mean, µ1,g0 230.00 222.38 210.96 199.54
2nd Nrv mean, µ2,g0 300.00 292.38 280.96 269.54
Overall mean, µg0 265.00 257.38 245.96 234.54
Intended RAR ratio, ρd 0.50 0.57 0.66 0.75
Nrv: Normal random variable
Distribution-specific parameter values are provided in Table 2.1, and visual displays of each
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Figure 2.2: Distribution-specific densities based on intended trial parameters
for simulation of treatment and control group response data by effect sizes.
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response distribution characterized by these parameter values are provided in Figure 2.2. With-
out loss of generality, the treatment group was considered superior to the control group when a
treatment difference existed (δ > 0.0); as such, the treatment group had a mean response value
that was lower than the mean response value of the control group. Also provided in Table 2.1
is the value of τ required to achieve 3:1 randomization (ρd = ρ0 = 0.75) when a large treatment
difference was observed. This tuning parameter also dictated ρd when a large treatment difference
was not observed. When no treatment difference existed (δ = 0.0), intended randomization was 0.5
(ρd = 0.5). Intended randomization ratios varied for small (δ = 0.2) and moderate (δ = 0.5) effect
sizes, and are provided in Table 2.1.
Results using preliminary data with 500 trial participants showed no differences in random-
ization for greater than 200 participants; therefore, the simulation studies were limited to 200
participants in each simulated trial. To produce the previously-described plots of the means and
95% CIs, the RAR ratios across 1,000 iterations of each of the 60 scenarios considered (3 non-
normal response distributions × 4 effect sizes × 4 methods of randomization + 1 normal response
distribution × 4 effect sizes × 3 methods of randomization) were collected for each of the 200 par-
ticipants enrolled. The means and variances of these 60 sets of 1,000 RAR ratios were calculated
and 95% CIs were constructed.
The ethical objective of RAR in these trials was to minimize the total expected response value
observed in the trial. Therefore, to construct the plot of the %O-E, group-specific sample means and
sample sizes were calculated after the enrollment of each subject into the trial, and their means
were calculated across all 1,000 trials. Then, using (1.1) from Section 1.3, the observed ethical
objective function was defined as:
Oi = n̂T i µ̂T i + n̂Ci µ̂Ci, (2.32)
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where n̂gi represents the mean observed number of subjects enrolled in group g from the first to
the ith participant, and µ̂gi represents the mean observed sample mean of group g from the first to
the ith participant enrolled into the trial over 1,000 simulated trials. Similarly, the expected ethical
objective function was defined as:
Ei = E(nT i) µT0 + E(nCi) µC0, (2.33)
where E(ngi) represents the mean expected number of subjects enrolled in group g from the first
the first to the ith participant enrolled into the trial over 1,000 simulated trials, where:
E(ngi) =

0.5 i, for i = 1, 2, · · · , L,
0.5 L + ρd (i− L), for i > L and g = T,
0.5 L + (1− ρd) (i− L), for i > L and g = C,
(2.34)
where L represents the lead-in size of the trial. Lead-ins are described in depth in the following
section. When no treatment difference exists, E(ngi) = 0.5 i for i = 1, 2, · · · , 200. With this, the
percent-difference between the observed and expected ethical objective function is defined as:
%O-E = 100 × (Oi − Ei) / Ei. (2.35)
2.2.1 Lead-in Analysis
Figure 2.1 shows that response-adaptive clinical trials require a lead-in period before RAR can
begin. During this lead-in period, a small number of trial participants are equally-randomized into
either the treatment or control group immediately following trial onset. The purpose of this lead-in
period is to accrue enough group-specific response data that the means and SDs that comprise the
RAR ratio can be estimated. Since the focus of the present chapter is the estimation of the means
and SDs that comprise the RAR ratio, particularly in small samples, initiating RAR as early as
possible by minimizing the lead-in period was important to the evaluation of the methods presented
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in this chapter. While Haines and Sadiq [43] evaluated start-up duration, a type of lead-in, no other
suggestions regarding lead-in size calibration exist in the literature. Therefore, an assessment of
possible lead-in lengths was performed in which participants were equally-randomized into the trial
using block randomization, selected because it produces an equal number of subjects in each group.
Other methods of ER may result in unequal group-specific lead-in sizes, equally-randomizing a
greater number of subjects into the trial than desired.
Figure 2.3: Process for selecting lead-in size for simulations used to evaluate the empirical
estimation methods using parametric continuous response data.
A visual depiction of the lead-in analysis is provided in Figure 2.3. To conduct the lead-in
analysis, 1,800 trials for each of the simulation scenarios described previously (§2.2) were performed
for increasing lead-in sizes, beginning with the block randomization of three subjects into each
group, i.e., lead-per-group (LPG) of three (LPG=3) for six subjects total (L=6). Due to the
complexity of the HEFT method of estimation versus PLKM and MLE estimation, LPG sizes were
incremented by one until LPG=20 (L=40) for RAR using the HEFT method of estimation, and
until LPG=10 (L=20) for RAR ratios estimated using either the PLKM method of estimation and
distribution-specific MLEs. If the means or SDs - and, subsequently, the RAR ratio - could not be
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estimated after a participant was enrolled, the simulated trial was stopped. The trial was deemed
successful when RAR ratios were estimated for all 200 subjects enrolled into the trial. The percent
of successful trials out of the 1,800 performed, denoted %success, was reported by LPG for each
simulation scenario.
Reiterating the goal of beginning RAR using the smallest possible lead-in size, a results-driven
sensitivity analysis based on the observed %success, denoted %̂success, was performed for scenarios
where the %̂success was less than 100 for LPG=3. In these scenarios, the LPGs where %̂success was
at least 65, 70, 75, and 80 were of-interest. The minimum %success value of 65 was selected because
it represents a majority of trials and each of the HEFT randomization scenarios for LPG=3 could
be considered in the sensitivity analysis. From 65, the desired %success value was incremented by
five until %success=80, at which point LPGs were too large to be practical.
Table 2.2: Lead-per-group at which at least 65, 70, 75, or 80% of trials were successful when
estimating the RAR ratio using HEFT moment estimation and when estimating the RAR
ratio using mixture distribution MLEs for mixture-distributed response data by effect size.
Desired LPG (%̂ success)
RAR Truth %success δ = 0.0 δ = 0.2 δ = 0.5 δ = 0.8
HEFT Normal 65 3 (68.9) 3 (71.5) 3 (73.2) 3 (75.8)
70 14 (72.3) 3 (71.5) 3 (73.2) 3 (75.8)
75 15 (80.6) 15 (81.5) 14 (77.3) 3 (75.8)
80 15 (80.6) 15 (81.5) 15 (80.4) 11 (80.3)
Gamma 65, 70 3 (71.8) 3 (76.1) 3 (77.0) 3 (77.6)
75 15 (77.1) 3 (76.1) 3 (77.0) 3 (77.6)
80 16 (89.7) 16 (91.6) 14 (83.0) 12 (80.2)
X2U 65, 70, 75, 80 3 (83.1) 3 (82.7) 3 (84.3) 3 (89.6)
NM 65, 70, 75, 80 3 (82.3) 3 (81.6) 3 (82.9) 3 (84.7)
X2U X2U 65, 70 5 (72.7) 5 (72.2) 5 (74.9) 5 (78.5)
75 6 (81.7) 6 (82.5) 6 (84.3) 5 (78.5)
80 6 (81.7) 6 (82.5) 6 (84.3) 6 (85.4)
NM NM 65, 70 7 (76.7) 7 (77.9) 7 (74.6) 7 (77.1)
75 7 (76.7) 7 (77.9) 8 (85.9) 7 (77.1)
80 8 (86.7) 8 (86.3) 8 (85.9) 8 (86.2)
Regardless of the simulated response distribution, all 1,800 trials were successful when subjects
were randomized into the trial by estimating the RAR ratio using the PLKM method and normal
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MLEs for LPG=3. Likewise, all 1,800 trials were successful for LPG=3 when using gamma MLEs
to estimate the RAR ratio for response data simulated to follow the gamma distribution. Results
varied for HEFT randomization and mixture randomization of mixture-distributed response data,
and are provided in Table A.15 in the Appendix. These scenarios were considered in the sensitivity
analysis, and results are provided in Table 2.2.
Specific to HEFT randomization of response data following the normal and gamma distributions,
a large increase in LPG was required to observe at least 75 or 80 versus 65 or 70 %success. This
represents the difference between equally-randomizing six subjects for the 65-70 %success situation
compared to 20-30 for the 75-80 %success situation prior to initiating RAR. Where the present
work seeks to evaluate the behavior of various methods of estimating the RAR ratio with an
emphasis on small-sample estimation, large lead-in sizes such as these may severely hinder the
practicability of the HEFT method and damage the interpretation of its results, particularly when
compared to randomization methods requiring much smaller lead-in sizes. Though randomization
using larger lead-in sizes may have been more well-behaved in some scenarios (e.g., LPG=12 versus
LPG=3 for HEFT randomization of gamma-distributed responses), obtaining empirically-estimated
RAR ratios in small samples was more important to the present work than obtaining albeit better-
behaved estimated RAR ratios that required three-to-four times the number of subjects in the lead-
in period to be estimated. Finally, with respect to mixture randomization of mixture-distributed
response data, randomization results based on the LPG required to obtain 65, 70, and 75 %success
were nearly identical to the randomization results obtained using the LPG required to observe 80
%success.
Whether HEFT randomization of normal or gamma response data or mixture randomization
of mixture-distributed response data, this sensitivity analysis confirmed that overall trial results
will not change when randomization is based on the LPG necessary for 65 versus 80 %success: at
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Figure 2.4: Mean of RAR ratios with 95% CI (A) and percent-difference between the ob-
served and expected ethical objective function (B) over 1,000 simulated trials where normally-
distributed group-specific subject responses reflected a large treatment difference and were
randomized using the HEFT empirical estimation method, for LPG=3, whereby at least 65,
70, and 75 %success was observed, and for LPG=11, whereby at least 80 %success was ob-
served.
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Figure 2.5: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed gamma distributions that reflected a large treatment difference and
were randomized using the HEFT empirical estimation method, for LPG=3, whereby at least
65, 70, and 75 %success was observed, and for LPG=12, whereby at least 80 %success was
observed.
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Figure 2.6: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed X2U distributions that reflected a large treatment difference and
were randomized using RAR ratios estimated using X2U MLEs, for LPG=5, whereby at least
65, 70, and 75 %success was observed, and for LPG=6, whereby at least 80 %success was
observed.
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Figure 2.7: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed NM distributions that reflected a large treatment difference and
were randomized using RAR ratios estimated using NM MLEs, for LPG=7, whereby at least
65, 70, and 75 %success was observed, and for LPG=8, whereby at least 80 %success was
observed.
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most, one or two subjects for every 100 enrolled into the trial may be randomized to the treatment
group opposite from the one intended by the trial design. Such a difference is likely insufficient to
influence the final results of the clinical trial. And, finally, the purpose of employing RAR is to
balance the power of the clinical trial against an ethical objective. When using the LPG required
to observe 65 %success, observed randomization minimized the overall mean response value either
better than or not dissimilarly to trials using LPG required to observe 80 %success because a larger
number of subjects underwent RAR versus ER. For these reasons, lead-in sizes were selected based
upon the LPG required to observe at least 65 %success for each scenario. With the exception of
mixture randomization of mixture-distributed responses, this was LPG=3. Lead-per-group of five
and LPG=7 were used for X2U randomization of X2U response data and NM randomization of
NM response data, respectively. With this, corresponding values of L for the calculation of Ei were
L=6 save for the former, where Ei was based on L=10 and L=14, respectively.
2.3 Randomization Results
Results for simulated RCTs with continuous outcomes are discussed in what follows. All curves
were loess-smoothed using a bandwidth of 0.075. Randomization results for small and moderate
effect sizes followed patterns similar to those discussed in the following sections and are, therefore,
provided in Appendices A.16-A.23.
2.3.1 Normal Response Data Scenarios
In the baseline scenario (δ = 0.0) where group-specific response data were normally-distributed and
reflected no treatment difference (Figure 2.8), randomization behaved as anticipated under RAR:
an approximately equal number of participants were randomized to either treatment group (grey
line at ρd = 0.5; plot A) and any deviations from the intended ethical objective function were less
than 0.2% (plot B). Furthermore, as displayed in Table 2.3, type I error was well-controlled: no
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Figure 2.8: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials when group-specific
subject responses were normally-distributed and reflected no treatment difference.
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Table 2.3: Assessment of type I error by scenario using t-test based on observed mean response
from first 100 trial participants enrolled when no treatment difference existed (δ = 0.0) from
1,000 simulated trials.
Truth RAR Treatment Mean Control Mean t p-value
Normal HEFT 100.09 100.12 -0.498 0.6187
PLKM 100.14 100.18 -0.746 0.4555
Normal 100.16 100.17 0.225 0.8219
Gamma HEFT 10.09 10.12 -0.811 0.4177
PLKM 9.990 10.01 -0.936 0.3494
Normal 10.07 10.10 -0.891 0.3733
Gamma 10.11 10.10 0.447 0.6550
X2U HEFT 25.33 25.22 1.543 0.1229
PLKM 25.30 25.18 1.541 0.1235
Normal 25.30 25.25 0.654 0.5132
X2U 25.32 25.27 1.111 0.2665
NM HEFT 266.01 266.06 -0.145 0.8850
PLKM 265.85 265.96 -0.336 0.7371
Normal 265.80 265.56 0.824 0.4102
NM 265.45 265.44 0.075 0.9402
unsubstantiated treatment differences were detected.
When group-specific subject responses were normally-distributed and a large difference existed
(Figure 2.9), ¯̂ρH (red solid curve) was less biased than ¯̂ρP (blue solid curve) with respect to both
¯̂ρT (black dashed curve) and ρd (grey line at ρd = ρ0 = 0.75) (plot A). Specifically, ¯̂ρP followed the
same overall trend as ¯̂ρH, but with an additional bias of approximately 0.02. As well, any deviations
from the intended ethical objective of the trial were less than three percent, and existed primarily
during the lead-in period (plot B, Figure 2.9).
2.3.2 Non-normal Response Data Scenarios
When response data were not normally-distributed and no treatment difference was observed,
randomization using either PLKM or HEFT produced an approximately equal number of subjects in
each group (Figure 2.10), and %O-E never exceeded two (Figure 2.11). When response data followed
the gamma distribution and a large treatment effect was observed, ¯̂ρH, ¯̂ρP, and ¯̂ρT performed
similarly, but did not converge to ρd (plot A, Figure 2.12). Furthermore, though %O-E was less
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Figure 2.9: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials when group-specific
subject responses were normally-distributed and a large treatment difference existed.
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Figure 2.10: Mean of RAR ratios with 95% CI over 1,000 simulated trials when group-
specific subject responses were not normally-distributed and reflected no treatment dif-
ference.
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Figure 2.11: Percent-difference between the observed and expected ethical objective func-
tion over 1,000 simulated trials when group-specific subject responses were not normally-
distributed and reflected no treatment difference.
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Figure 2.12: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the gamma distribution and reflected a large difference.
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than two for all methods of randomization following the lead-in period, RAR using PLKM deviated
furthest from the intended ethical objective function, followed by randomization under the HEFT
method (plot B, Figure 2.12).
A y-axis ranging from ρd ± 0.05 was required to display the mean randomization results when
group-specific response data followed X2U mixture distributions reflecting a large treatment differ-
ence versus the more restricted range of ρd ± 0.03 (light-grey dashed lines) sufficient for presenting
mean randomization results for all other scenarios (plot A, Figure 2.13). In this scenario, neither
empirical estimation method achieved ρd and ¯̂ρP remained dissimilar to ¯̂ρT for all 200 participants
enrolled into the simulated trials while ¯̂ρH was only marginally similar to ¯̂ρT for the final 125
participants enrolled.
The y-axis of plot B in Figure 2.13 extends to 40 versus the maximum %O-E y-axis value of
18 (light-grey dashed line) sufficient for displaying the %O-E results in all other scenarios. This
suggests that the means obtained using the X2U MLEs during the lead-in period were considerably
different from the intended X2U means in Table 2.1. After the lead-in period, the observed ethical
objective function deviated by approximately four percent when the RAR ratio was estimated
using the PLKM and HEFT methods and declined to roughly two percent as more participants
were enrolled into the trial.
Finally, when response data followed the bimodal mixture of two normal random variables and a
large treatment difference was observed, ¯̂ρP and ¯̂ρH performed similarly but failed to mirror ¯̂ρT from
the 50th participant onward (plot A, Figure 2.14). As well, neither empirical estimation method
converged to ρd. However, all methods of randomization adhered to the ethical objective of RAR
(plot B, Figure 2.14).
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Figure 2.13: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the X2U distribution and reflected a large difference.
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Figure 2.14: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the NM distribution and reflected a large difference.
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2.4 Conclusion
Evidenced by the lead-in analysis, estimation of the moments for the RAR ratio may be contin-
gent upon the lead-in size, particularly for non-exponential family distributions. Therefore, it is
recommended in practice to use the ratio prior to the subject for which the moments cannot be
estimated as that subjects RAR ratio, then continue adding blocks of, for example, two or four.
Where the focus on the evaluation and implementation of the empirical RAR ratios versus the
appropriateness of the lead-in period chosen for the present analysis, the cut-off of a 65% success
rate for LPG=3 was selected. For HEFT lead-in, the estimation of moments was more successful
for more complex response data (i.e., mixture distributions) versus simple response distributions
(i.e., gamma or normal). This may be because HEFT uses a more complex algorithm to select
knots, beginning with three knots placements, which may have been harder to place with simpler
distributions. For example, if using quadratic splines to model the response data with a single
unknown factor, there exists at least seven parameters to estimate, one for each intercept, slope,
and quadratic term on either side of the knot, plus a variance term. Adding in the continuity
restriction of the mean and its derivative, this becomes a numerical challenge in smaller samples.
As anticipated, however, larger effect sizes were more easily detected in smaller samples. [24]
Overall, empirical estimation of the operands of the moments using the HEFT and PLKM
methods recreated true randomization and upheld the ethical objective of the trial, yet HEFT
estimation produced more well-behaved estimates than the PLKM method. For X2U response
data, the normal RAR ratio randomized better than the X2U RAR ratio with respect to achieving
and maintaining 3:1 randomization. Because the X2U RAR ratio never converged to 3:1 ran-
domization, it may be true that the BBZ optimal RAR ratio is not appropriate for such heavily
skewed response data Even though HEFT most closely matched X2U randomization, %O-E showed
about 5% deviation for HEFT and PLKM randomization versus approximately zero deviation for
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normality, suggesting the normality assumption holds. For NM response data, again, HEFT and
PLKM randomization performed well with respect to trial design, but were still outperformed by
the normality assumption.
Overall, HEFT and PLKM randomization produced estimates of the RAR ratio that closely
adhered to those expected by the trial design. That is, resulting randomization ratios fell to
within 0.02 of the intended 3:1 randomization and %O-E ≤ 5 in nearly all scenarios. However,
randomization under the normality assumption best-adhered to the trial design regardless of the
shape of the response data, even in small samples. Therefore, it is suggested to assume normality
in practice.
Of course, though RAR under the normality assumption was comparable in most cases, not
every distribution was considered in the present work. Users of these methods may consider sit-
uations where there is concern about the use of the sample mean under normality or they may
consider alternative methods of approximating the CDF besides HEFT or PLKM, the only two
approaches employed in the present work. Alternative distributional assumptions or methods of
CDF estimation may out-perform normality; further investigation may be required.
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Chapter 3
Robust Randomization of Continuous Response Data
Using the Weighted Average
3.1 The Weighed-Average Framework
In Chapter 2, the operands of the robust RAR ratio were estimated empirically. The methodology
discussed in the present chapter sought to obtain a robust estimator of the RAR ratio directly
by employing a weighted average (WA) framework that automatically adjusted for distributional
uncertainty. [42] That is, where many model selection techniques systematically neglect uncertain-
ty, weighted-averaging characteristically incorporates randomness in order to improve model fit by
selecting or combining a variety of models in a manner conducive to the observed data. [42] Since av-
eraging over competing models offers results that are more robust than those derived from analyses
dependent upon a single selected model, weighted-averaging is an inherently-robust framework. [42]
Fragoso [42] and Hoeting [44] contain pertinent examples of the WA framework. Therefore, in the
present chapter, participants were randomized into the trial using RAR ratios estimated assuming
a set of predetermined continuous distributions, i.e., candidate response distributions (CRD) in
lieu of removing the distributional assumption altogether (as in Chapter 2). The resulting set of
CRD-specific RAR ratios were then weighted by that CRD’s fit to the observed response data, the
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combination of which produced a flexible, inherently robust estimator of the RAR ratio. [42,44]
3.1.1 Methodology
For K CRDs, let dk be the value that represents the k
th (k = 1, · · · ,K) CRD fit to the observed
response data based on some measure-of-fit (MOF) where smaller values indicate better fit. Ex-
amples of such MOFs include Akaike information criterion (AIC), Bayesian information criterion,
Kullback-Leibler distance, the Kolmogorov-Smirnov (KS) test statistic, the Cramer von-Mises cri-
terion, or the Kuiper’s test statistic. [45–50] As well, let d0 be a reference MOF value that serves to
scale each of the K MOF values. Letting smaller MOF values indicate a better distributional fit
to the data, the minimum dk value was set as d0. As such, the scaled MOF values were provided
by the difference between each dk and d0, denoted d
∗
k, i.e.,
d∗k = dk − d0. (3.1)
Inducing a scale in this manner gives meaning to otherwise-meaningless individual MOF values,
allowing direct comparison of the distributional fits produced by each CRD. [45] Since the individual
MOF values are positive, real-valued numbers, scaling also alleviates much of the potential compu-
tational burden engendered by their direct use. [45] The difference given in (3.1) is the cornerstone











where wk ∈ (0, 1) and
∑K
k=1wk = 1. These distributional weights may be interpreted as the weight
of evidence suggesting that CRD k is the distribution that best-fits the observed response data in
the set of K CRDs under consideration, assuming a best-fitting CRD exists in the considered set. [45]
Under this weighting scheme, more heavily-weighted CRDs, i.e., CRDs with weights closer to one,
were said to better-fit the observed response data than CRDs with wk closer to zero. Explicitly, the
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WA-estimated RAR ratio representing the probability of randomizing subject i+1 to the treatment





where ŵik represents the MOF-estimated distributional weight and each ρ̂k takes the form of 1.18,
where σ̂gi and µ̂gi were estimated using the MLEs specific to each CRD k.
3.2 Simulation Process for Evaluation of Weighted-Average Randomization
A simulation study was performed to determine how well the WA method of RAR accounted for
distributional misspecification of the RAR ratio. The goal of this simulation study was identical
to those discussed in Section 2.2: to evaluate the bias, precision, and ethicality of the method-
produced estimator of the RAR ratio using plots of the mean RAR ratios from 1,000 trials and
their 95% CI along with the %O−E plot. Specifically, the mean WA RAR ratio (ρ̂WA) was compared
ρ̂T and ρd. Since more heavily-weighted CRDs represent larger proportions of the WA-estimated
RAR ratio, the behavior of the CRDs when fit to the observed response data was also of interest,
and was assessed using plots of the means of the CRD-specific weights across the 1,000 simulated
trials for each of the 200 subjects enrolled into the trial. As well, an assessment of type I error was
performed as in Chapter 2, and results were presented by Set (discussed later in this section).
Figure 3.1 provides a visual representation of the WA simulation study. As in Section 2.2,
response data were simulated to follow the normal, gamma, X2U, and NM distributions, character-
ized by the parameters given in Table 2.1. New to the simulation process was the estimation of the
RAR ratios corresponding to each CRD within a predetermined set of CRDs. Overall, six CRDs
were considered: the normal, Laplace, and logistic distributions, selected for their symmetry, and
the gamma, Weibull, and lognormal distributions, selected for their ability to incorporate skewness.
Derivation of the MLEs corresponding to the Laplace, logistic, Weibull and lognormal distributions
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Figure 3.1: Simulation process for evaluation of WA method of RAR using parametric contin-
uous response data.
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are provided in Appendices A.24-A.27, respectively. When the treatment-specific response data
were simulated to follow normal and gamma distributions, these CRDs were arranged into distinct
sets designed to assess the behavior of WA RAR when multiple hypothetically well-fitting and/or
poorly-fitting CRDs were considered within the same set. Specifically, four sets were evaluated:
• Set 1: Truth, two hypothetically well-fitting CRDs, and one hypothetically poorly-fitting
CRD,
• Set 2: Truth, one hypothetically well-fitting CRD, and two hypothetically poorly-fitting
CRDs,
• Set 3: Truth and three hypothetically poorly-fitting CRDs, and,
• Set 4: One hypothetically well-fitting CRD and two hypothetically poorly-fitting CRDs (i.e.,
no truth),
where CRDs were hypothesized to fit the simulated response data well or poorly based on the
symmetrical or skewed nature of the CRD in relation to the shape of the true distribution of the
simulated response data. Because the truth was included in Sets 1-3, it was hypothesized to be the
most heavily-weighted, and, thus, best-fitting CRD in these three sets.
Table 3.1: Candidate response distributions within each simulation set when treatment-specific
response data were simulated to follow the normal (N), gamma (G), X2U, and NM distribu-
tions.
CRDs Set 1 Set 2 Set 3 Set 4
Symmetrical:
Normal N∗ G N∗ G N∗ G G X2U NM∗
Laplace N N G G N∗ G X2U NM
Logistic N G
Skewed:
Gamma N G∗ N G∗ N G∗ N X2U∗ NM
Weibull G N G N N G∗ X2U∗ NM
Lognormal G N
∗Hypothesized to be best-fitting CRD(s) within set for response distribution indicated
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Table 3.1 details which of the six CRDs falls into each set according to the true response
distribution being simulated. Of particular interest was Set 4, designed to illustrate the behavior of
WA randomization when the true response distribution was not considered among the candidates.
In these scenarios, the best-fitting CRD was hypothesized to be the CRD that most closely matches
the known shape of the simulated response data. Best-performing CRDs were indicated in Table
3.1 with an asterisk. Where Sets 1-3 considered scenarios where response data followed only the
exponential families of the normal and gamma distributions, Set 4 was also applied to the more
complex mixture distributions of X2U and NM. These scenarios were included because the RAR
ratio would very likely be misspecified if response data followed distributions such as these in
practice. Such distributions would be unlikely to be considered as candidates if employing the WA
approach. Thus, Set 4 represents weighted-averaging over a set of simpler CRDs may serve to
alleviate the likely misspecification of the RAR ratio that could occur in practice. Table 3.1 shows,
two symmetrical and two skewed CRDs were considered when response data were truly X2U- or
NM-distributed: the normal and Laplace (symmetrical) and the Weibull and gamma (skewed)
distributions. Because the X2U distribution is heavily right-skewed (Figure 2.2), it was anticipated
that either the gamma or Weibull distribution, or both, would out-weigh the symmetrical CRDs.
And, when response data followed bimodal NM distributions, it was hypothesized that the normal
distribution would be the most heavily-weight CRD.
Results from the lead-in analysis discussed in Section 2.2.1 were applied to these simulations
such that all CRDs began RAR after LPG=3 and RAR when response data were simulated to
follow the X2U and NM distributions, performed for comparison purposes, began after LPG=5
and LPG=7, respectively. Furthermore, two MOFs were used to develop the CRD-specific weights:
AIC [45] and the KS test statistic [48]. Finally, simulations were conducted for no treatment difference
(δ = 0.0) and a large treatment difference (δ = 0.8). Small and moderate effect sizes were omitted
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from the present simulation study based on the results observed in Chapter 2.
3.3 Randomization Results
All curves were loess-smoothed using a bandwidth of 0.2. As illustrated in plot B of both Figures 3.2
and 3.3, the KS test statistic poorly distinguished between CRDs, indicated by mean distributional
weights falling within two- and four-thousandths, respectively, of equal weighting (grey horizontal
line at 1/K). Therefore, randomization results with respect to AIC-weighting are discussed in this
section.
3.3.1 Absence of Treatment Difference
When treatment-specific response data were simulated to follow the normal distribution in the
absence of a treatment difference, randomization proceeded as expected for CRD sets containing
normality (Sets 1-3). That is, ρ̂WA, as well as each CRD-specific mean RAR ratio, approximated
ρd = 0.5 (Figure 3.4), and the true response distribution, normality (green curve), was most heavily-
weighted across CRD sets (Figure 3.5). The mean distributional weight for the true response
distribution, ŵT , went to one (i.e., ŵT → 1) almost immediately following the lead-in period for
CRD Set 2 (plot B). This suggests that, in addition to the skewed gamma (blue curve) and Weibull
(red curve) distributions, the Laplace distribution (purple curve) does not fit normally-distributed
response data well either, despite its symmetry. Further evidence to this point is provided in plot
A (CRD Set 1), where the mean distributional weight for the Laplace CRD, ŵLa, went to zero,
ŵT → 0. When all non-truth CRDs were skewed (plot C, CRD Set 3), the mean distributional
weight for the Weibull CRD, ŵW , went to zero (i.e., ŵW → 0) while the mean distributional weights
for the gamma and lognormal CRDs, ŵG and ŵlogN , respectively, approximated equal weighting at
1/K. Finally, all CRDs and WA (black curve) RAR upheld the ethical objective of RAR to within
0.3% (Figure 3.6), despite the %O-E for the Weibull CRD increasing as the number of participants
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Figure 3.2: Mean of RAR ratios with 95% CI (A), mean of KS-based distributional weights
(B), and percent-difference between the observed and expected ethical objective function (C)
over 1,000 simulated trials when treatment-specific participant response data were normally-
distributed and reflected a large treatment difference, and CRDs were the normal, gamma,
Weibull, and Laplace distributions (i.e., CRD Set 2).
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Figure 3.3: Mean of RAR ratios with 95% CI (A), mean of KS-based distributional weights
(B), and percent-difference between the observed and expected ethical objective function (C)
over 1,000 simulated trials when treatment-specific participant response data were simulated
to follow the gamma distribution and reflected a large treatment difference, and CRDs were
the normal, gamma, Weibull, and Laplace distributions (i.e., CRD Set 2).
54
Figure 3.4: Mean of CRD-specific and WA RAR ratios with 95% CI over 1,000 simulated
trials when treatment-specific participant responses were normally-distributed and reflected
no treatment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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Figure 3.5: Mean of AIC-estimated distributional weights from 1,000 simulated trials when
treatment-specific participant responses were normally-distributed and reflected no treatment
difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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Figure 3.6: Percent-difference between the observed and expected ethical objective func-
tion from 1,000 simulated trials when treatment-specific participant responses were normally-
distributed and reflected no treatment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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enrolled into the trial increased.
When treatment-specific response data were simulated to follow the gamma distributions in
the absence of a treatment difference, neither ρ̂WA nor any of the CRD-specific mean RAR ratios
deviated from ρd = 0.5 for any of the 200 participants enrolled into the trial (Figure 3.7). Further-
more, across CRD sets, the gamma distribution (green curve) was consistently weighted heaviest
(Figure 3.8), as anticipated. The two skewed CRDs, Weibull (red curve) and lognormal (purple
curve), fit the gamma-distributed response data equally well and better than the symmetrical nor-
mal distribution (blue curve) for CRD Set 1 (plot A). Maintaining this trend, the skewed Weibull
distribution better-fit the skewed gamma-distributed response data than the symmetrical CRDs
of normality and the Laplace distribution (purple curve) (plot B, CRD Set 2). Finally, when all
non-truth CRDs were symmetrical, weights quickly went to zero following the lead-in period, while
ŵT → 1 (plot C, CRD Set 3).
Table 3.2: Assessment of type I error for normal or gamma response data
for Sets 1-3 using t-test based on observed mean response from first 100 trial
participants enrolled when no treatment difference existed (δ = 0.0) across
1,000 simulated trials.
Truth Set Treatment Mean Control Mean t p-value
Normal 1 100.14 100.12 0.396 0.6925
2 100.10 100.15 -0.977 0.3288
3 100.09 100.13 -0.774 0.4393
Gamma 1 10.11 10.10 0.052 0.9584
2 10.10 10.09 0.449 0.6537
3 10.15 10.09 1.519 0.1290
As indicated by ŵLa → 0 in plot B and both the mean distributional weight for the logistic
CRD, ŵlo, and ŵLa going to zero in plot C of Figure 3.8, the WA RAR was not heavily influenced
by the Laplace or logistic CRDs, especially after the 50th trial participant was enrolled. Therefore,
without loss of generality, %O-E for the Laplace CRD alone and both the Laplace and logistic CRDs
were omitted from plots B and C, respectively, of Figure 3.9 due to lack of interpretability. Across
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Figure 3.7: Mean of CRD-specific and WA RAR ratios with 95% CI over 1,000 simulated trials
when treatment-specific participant responses were simulated to follow gamma distributions
reflecting no treatment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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Figure 3.8: Mean of AIC-estimated distributional weights from 1,000 simulated trials when
treatment-specific participant responses were simulated to follow gamma distributions reflect-
ing no treatment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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Figure 3.9: Percent-difference between the observed and expected ethical objective function
from 1,000 simulated trials when treatment-specific participant responses were simulated to
follow gamma distributions reflecting no treatment difference using CRD Sets 1 (A), 2 (B),
and 3 (C).
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CRD sets, %O-E never exceeded 1.75, suggesting that all of the CRD-specific and WA (black curve)
RAR ratios successfully adhered to the ethical objective of minimizing the mean response value of
the trial. Finally, no type I errors were committed in the scenarios assessed, as evidenced by Table
3.2.
3.3.2 Large Treatment Difference
When treatment-specific response data were simulated to follow normal distributions reflecting a
large treatment difference, WA RAR (Figure 3.10, black curve) favored the RAR ratio estimated
assuming normality (Figures 3.10 and Figure 3.11, green curve), regardless of the set of CRDs
considered. All other distributional weighting trends observed in Figure 3.11 were identical to
those observed in Figure 3.5. As well, all CRDs randomized participants similarly, regardless of
CRD set, and all mean RAR ratios, both CRD-specific and WA-estimated, nearly converged to
ρd (Figure 3.10). Finally, all of the CRD-specific RAR ratios as well as the WA method of RAR
adhered to the ethical objective of the trial (Figure 3.12). During the lead-in period, all %O-E were
less than or equal to three, then fell to and remained below 0.5%. Though a small difference, the
%O-E for the Weibull CRD shows a pattern dissimilar to the %O-E for other CRDs and for WA
RAR (plots B and C), mirroring the results presented in plots B and C of Figure 3.6.
When treatment-specific response data were simulated to follow gamma distributions reflecting
a large treatment difference, each CRD, as well as WA RAR (black curve), randomized trial par-
ticipants similarly (plots B and C) or nearly identically (plot A), depending on the set of CRDs
considered (Figure 3.13). All mean RAR ratios converged to approximately ρd + 0.05 and over-
randomized to the treatment group for all trial participants following the lead-in period, with one
exception: when all non-truth CRDs were symmetrical (plot C, CRD Set 3), ρ̂La (purple curve)
achieved and maintained ρd (grey horizontal line) from the 50
th participant onward. However, as
illustrated by plot C in Figure 3.14, ŵT → 1 (green curve) while all other weights, including the
62
Figure 3.10: Mean of CRD-specific and WA RAR ratios with 95% CI over 1,000 simulated
trials when treatment-specific participant responses were normally-distributed and reflected a
large treatment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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Figure 3.11: Mean of AIC-estimated distributional weights from 1,000 simulated trials when
treatment-specific participant responses were normally-distributed and reflected a large treat-
ment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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Figure 3.12: Percent-difference between the observed and expected ethical objective func-
tion from 1,000 simulated trials when treatment-specific participant responses were normally-
distributed and reflected a large treatment difference using CRD Sets 1 (A), 2 (B), and 3
(C).
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Figure 3.13: Mean of CRD-specific and WA RAR ratios with 95% CI over 1,000 simulated trials
when treatment-specific participant responses were simulated to follow gamma distributions
reflecting a large treatment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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Figure 3.14: Mean of AIC-estimated distributional weights from 1,000 simulated trials when
treatment-specific participant responses were simulated to follow gamma distributions reflect-
ing a large treatment difference using CRD Sets 1 (A), 2 (B), and 3 (C).
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ŵLa, went to zero. Therefore, despite the Laplace-specific RAR ratio’s ability to randomize par-
ticipants as intended by the trial design in this particular setting, it had negligible influence over
the WA RAR ratio used to enroll participants into the trial. The remaining distributional weight
patterns gleaned in Figure 3.14 were nearly identical to those displayed in the baseline scenario
(Figure 3.8).
Laplace RAR produced substantial deviation from the intended ethical objective function when
included in the CRD set (Figure 3.15, plots B and C), stabilizing between a 7.5-9% discrepancy.
Similarly, RAR assuming the logistic distribution stabilized around a 4.5% deviation between the
observed and intended ethical objective function (plot C, red curve). Echoing the baseline scenario
(Figure 3.9), since ŵLa and ŵlo went to zero, the %O-E results for the Laplace and logistic CRDs
were not considered in the interpretation of these results, though they were maintained on plots
B and C since their inclusion does not compromise or alter the presentation of the meaningful
%O-E results. With this, Figure 3.15 illustrates that %O-E was less than 15 for all CRDs, as well
as for the WA method, during the lead-in period. Subsequently, this deviation diminished to and
remained below 1.75%, consistent with the results obtained from the baseline scenario. Therefrom,
all estimated RAR ratios fulfilled the ethical objective of the trial.
3.3.3 Truth Removed from Candidacy
Of particular emphasis was the behavior of WA RAR when the true response distribution was
not considered within the set of candidates (i.e., Set 4). In the previously-discussed results, the
true response distribution was the CRD favored during randomization. This allowed for straight-
forward results dissemination: overall, CRD-specific RAR and WA RAR behaved similarly and
distributional weights identified the true response distribution as the best-fit CRD. When the true
response distribution was removed from candidacy, however, randomization results were more com-
plex, requiring more careful visualizations. The plots of the mean RAR ratios were divided into and
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Figure 3.15: Percent-difference between the observed and expected ethical objective function
from 1,000 simulated trials when treatment-specific participant responses were simulated to
follow gamma distributions reflecting a large treatment difference using CRD Sets 1 (A), 2
(B), and 3 (C).
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presented using two figures: a plot representing ρ̂WA with respect to the hypothetically-unknown
ρ̂T and ρd (designated plot A-I), and a plot displaying RAR assuming each of the CRDs (designated
plot A-II).
When group-specific response data were simulated to follow normal distributions reflecting
a large treatment difference and the set of CRDs contained the gamma, Weibull, and Laplace
distributions,the resulting WA RAR ratio (dashed green curve) favored normality despite it not
being considered among the candidates (Figure 3.16, plot A-I). Moreover, ρ̂WA ≈ ρd (grey horizontal
line) for the final 100 participants enrolled into the trial. Though all CRDs randomized similarly
(plot A-II), ŵG → 1 while ŵW and ŵLa went to zero, suggesting that the gamma CRD, versus the
hypothesized Laplace CRD, best-fit the normally-distributed response data. Finally, the ethical
objective of RAR was upheld, where, following the lead-in period, %O-E was less than one-half
percent for all RAR ratios (plot C).
When treatment-specific response data were simulated to follow gamma distributions reflecting
a large treatment difference, the WA RAR ratio (black solid curve, plot A-I, Figure 3.17), obtained
from the skewed Weibull (red curve, plot A-II) and symmetrical normal (blue curve, plot A-II) and
Laplace distribution (purple curve, plot A-II) RAR ratios as weighted by AIC, closely mirrored RAR
conducted assuming the true gamma distribution (dashed green curve, plot A-I). As anticipated,
versus the symmetrical normal or Laplace CRDs, the WA RAR ratio was driven by the fit of the
skewed Weibull CRD to the skewed gamma-distributed response data, demonstrated in plot B
where ŵW → 1 and both the mean distributional weight for the normal CRD, ŵN , and ŵLa went
to zero following the lead-in period. Similar to the scenarios where the gamma distribution was
included within the set of CRDs (Figures 3.9 and 3.15), each of the CRD-specific and WA RAR
ratios adhere to the ethical objective of the trial with the exception of the uninterpretable Laplace
CRD (plot C).
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Figure 3.16: Comparison of mean WA RAR ratio against mean true response distribution
(non-candidate) RAR ratio (95% CIs) (A-I), mean RAR ratios (95% CIs) for each CRD (A-
II), mean of AIC-based distributional weights (B), and percent-difference between the observed
and expected ethical objective function (C) over 1,000 simulated trials when treatment-specific
participant responses were simulated to follow normal distributions reflecting a large treatment




Figure 3.17: Comparison of mean WA RAR ratio against mean true response distribution
(non-candidate) RAR ratio (95% CIs) (A-I), mean RAR ratios (95% CIs) for each CRD (A-
II), mean of AIC-based distributional weights (B), and percent-difference between the observed
and expected ethical objective function (C) over 1,000 simulated trials when treatment-specific
participant responses were simulated to follow gamma distributions reflecting a large treatment




Figure 3.18: Comparison of mean WA RAR ratio against mean true response distribution
(non-candidate) RAR ratio (95% CIs) (A-I), mean RAR ratios (95% CIs) for each CRD (A-
II), mean of AIC-based distributional weights (B), and percent-difference between the observed
and expected ethical objective function (C) over 1,000 simulated trials when treatment-specific
participant responses were simulated to follow X2U distributions reflecting a large treatment





When treatment-specific response data were simulated to follow X2U distributions reflecting
a large treatment difference, the WA RAR ratio (black solid curve, plot A-I, Figure 3.18) close-
ly recreated X2U RAR (green dashed line, plot A-I) by averaging over AIC-weighted RAR ratios
assuming the skewed gamma (blue curve, plot A-II) and Weibull (red curve, plot A-II) and symmet-
rical normal (gold curve, plot A-II) and Laplace (purple curve, plot A-II) CRDs. The MLEs for the
Weibull and Laplace CRDs produce estimated moments dissimilar to those of the X2U-distributed
response data, as evidenced by ρ̂W ∈ (0.80, 0.85) and ρ̂La → 0.9 in plot A-II. With this, ŵW and
ŵLa → 0, the latter doing so immediately following the lead-in period, suggesting that the Weibull
and Laplace CRDs poorly-fit the X2U-distributed response data (plot B). As well, following the
lead-in period until the 25th trial participant was enrolled, the normal distribution best-fit the X2U
response data; following the 25th trial participant, however, ŵG → 1, as anticipated. Finally, %O-E
for each of the CRD-specific and WA RAR ratios converged to less than five percent deviation,
though the X2U RAR converged slowest (plot C).
When treatment-specific response data were simulated to follow NM distributions reflecting a
large treatment difference, ρ̂WA (black curve) successfully approximated ρ̂T (green dashed line)
(plot A-I, Figure 3.19). And, as anticipated, the symmetrical normal CRD (gold curve) fit the
bimodal NM response distribution better than the symmetrical Laplace (purple curve) or skewed
gamma (blue curve) or Weibull (red curve) CRDs, indicated by ŵN → 1 and all other distributional
weights going to zero immediately following the lead-in period (plot B). Finally, all RAR ratios
adhered to the ethical objective of the trial (plot C).
3.4 Discussion
Weighted-average RAR performed well in a number of respects. First, the true response distribution
was consistently identified as the best-fit CRD when included in the set of CRDs, and more poorly-
fitting CRDs were given less weight, comprising less of the resulting RAR ratio. The latter was
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Figure 3.19: Comparison of mean WA RAR ratio against mean true response distribution
(non-candidate) RAR ratio (95% CIs) (A-I), mean RAR ratios (95% CIs) for each CRD (A-
II), mean of AIC-based distributional weights (B), and percent-difference between the observed
and expected ethical objective function (C) over 1,000 simulated trials when treatment-specific
participant responses were simulated to follow NM distributions reflecting a large treatment





demonstrated by the scenario in which response data followed skewed gamma or X2U distributions
and the symmetrical Laplace and logistic distributions were considered in the set of CRDs. These
CRDs produced misspecified RAR ratios as demonstrated by their respective %O-E being markedly
larger than that of the other methods of RAR. Consequently, the distributional weights for these
CRDs appropriately went to zero. Furthermore, when the truth was removed from the CRD set, WA
RAR closely approximated RAR assuming the true response distribution, despite the truth being
unknown in the methodology. Thus, the WA approach successfully incorporated distributional
uncertainty into the RAR process to produce a RAR ratio that was both ethical and powerful. [7,42]
Ideal randomization notwithstanding, additional considerations are advised if using this frame-
work. For example, the scale of the response data needs to be taken into account when selecting
CRDs. Overall, the skewed-versus-symmetrical paradigm of CRD selection produced expected
results for unimodal response distributions, meaning that symmetrical CRDs tended to produce
heavier weights than skewed CRDs when the observed response data was symmetrical, and vice
versa. However, the limiting distribution of a gamma random variable is normality. [24] As such, for
symmetrical response data with larger means, as in the normal response data derived in these sim-
ulations, the gamma distribution outweighed the symmetrical candidates. Another consideration
of this design is the MOF used to produce the distributional weights. Demonstrated by Figures 3.2
and 3.3, weighting based on the KS test statistic failed to markedly discriminate between distri-
butional fits to the observed response data, while AIC did so effectively, showing variability RAR
contingent upon the MOF used.
The X2U and NM scenarios were included because they most closely mimicked reality: the
true response distribution is complex and, thereby, unlikely to be considered in the set of CRDs.
When responses followed X2U distributions, though WA RAR mimicked X2U RAR, the ratios
themselves were considerably larger than those produced for the other response distributions, i.e.,
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normal, gamma, and NM. This may suggest that the optimal RAR procedure described in Section
1.3 may not be the most appropriate method of randomization for heavily-skewed response data.
Moreover, the normal CRD was most heavily-weighted until the 25th trial participant, as well as in
scenarios where response data were bimodal, suggesting that RAR under the common normality
assumption is innately robust against distributional misspecification, particularly in small samples,
and is, therefore, the recommended RAR ratio, overall. If choosing to perform RAR using the WA
method, however, selecting one or two symmetrical and skewed CRDs will result in a RAR ratio
that can mimic randomization under the true response distribution, even when response data are




Robust Randomization of Survival Response Data
4.1 Optimal RAR for Survival Data
Many RCTs use survival outcomes to measure treatment effectiveness and safety, though little
research and application has been conducted in RAR using such outcomes. [25,51,52] Examples of
survival response data include time-to-cancer progression in oncology or time-to-graft failure in
transplantation. [51] Censoring is a distinguishing characteristic of RCTs with survival outcomes.
This occurs when incomplete information regarding survival times exists for some trial participants.
Specifically, right-censoring would occur if a participant left the trial before trial completion in such
a way that the outcome was not observed and they were lost-to-follow-up. Therefore, RCTs using
RAR with right-censored survival outcomes can only rely upon the survival history of patients for
whom response data is available. [25] In the subset of RCTs with survival outcomes where recruitment
lasts long enough to where some patient outcomes may be observed before all patients have been
randomized into the trial, the optimal RAR method can be applied. [25]
Optimal RAR designs for survival outcomes have been developed in the context of interim
analyses, multi-arm, and group-sequential RCTs. [51,52,54] These designs are based on the Zhang
and Rosenberger (ZR) RAR design as it is convention given its simplicity and its ability to fit
neatly into the template proposed by Hu and Rosenberger. [25,53] In this framework, optimality,
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variability, and power are considered essential components of the valid RAR process. [25,53]
In the present work, the ZR RAR design with the importance criterion of minimizing the total
expected hazard of the trial was employed, versus ZR RAR designs targeting alternative importance
criteria. In this framework, survival times were assumed to be parametrically-distributed, following
either the exponential and Weibull distributions, where designs developed under the assumption of
the Weibull distribution were also applicable to other log-location-scale families. [25] Derivations of
the exponential and Weibull ZR RAR ratios are discussed in the following sections.
4.1.1 Optimal ZR RAR for Survival Times Following the Exponential Distribution
Survival times can be approximated by the exponential distribution in many RCTs, leading to
straightforward, closed-form theoretical results. [25] Suppose survival time Y follows an exponential
distribution with parameter θ, i.e., Y ∼ Exp(θ).i It, then, has the density and survival function
respectively given by:
fY (y) = exp(−y/θ)/θ, and, (4.1)
S(y) = exp(−y/θ), (4.2)
for θ > 0 and y > 0, else fY (y) = 0. Under this parameterization, Y has the constant hazard rate
of 1/θ, where θ is the mean survival time.
To derive the optimal RAR ratio, censoring must be incorporated in the modeling of the survival
times. Therefore, suppose that patients have survival times following the exponential distribution
as previously described, but which are also subject to an independent right-censoring scheme. Let
(yi, εi), i = 1, · · · , n, be a random sample from such a distribution, where, for the ith patient, εi = 1
iThe y versus t notation representing survival times introduced in Chapter 2 is maintained throughout the present
chapter, as well.
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and the loglikelihood is given by:





i=1 εi is the cumulative number of events and y =
∑n
i=1 yi is the sum of the observed
survival times, such that
d
dθ






Solving ddθ log{`(θ|y, ε)} = 0 gives the MLE of θ as θ̂ = y/r. As well, the Fisher information for θ,













Since the sum of n exponential random variables having parameter θ is a gamma random variable
with shape parameter n and scale parameter θ, in the absence of censoring, y ∼ Gamma(n, 1/θ).
When there is censoring, however, y ∼ Gamma(r, 1/θ) and E(y) can be approximated by θE(r).
Thus,
I(θ) = E(r)/θ2, (4.6)
and the approximate variance of θ̂ is:
V ar(θ̂) = 1/I(θ) = θ2/E(r). (4.7)
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Response-adaptive randomization is based upon the comparison of the parameters θT and θC ,
corresponding to mean survival times for treatment groups T and C, respectively. To derive the
optimal RAR ratio, consider two independent samples {(ygi, εgi); g ∈ {T,C}; i = 1, · · · , n}, and
assume that ξg = E(εgi) is the same for all i = 1, · · · , ng. Then E(rg) = ngE(εg1) = ngξg. With
this, the optimization process described in Appendix A.5 can be invoked to solve the following









































for survival outcome data with exponentially-distributed survival times. As described in Chapter
1, the parameters used to construct the RAR ratio are supplanted with its corresponding MLE
estimated from the response data obtained from patients who have already completed the trial.










4.1.1.1 Exponential Censoring Scheme
Zhang and Rosenberger employed a censoring scheme first introduced by Rosenberger and Seshaiy-
er and later expanded by Liu and Coad. [15,25,54] Given a fixed recruitment period R and trial
duration D, patient arrival times were assumed to follow an independent uniform distribution on
[0, R], i.e., U [0, R], while, independently, patients were subject to a censor time X that followed
a U [0, D] distribution. For a patient randomized to group g (g ∈ {T,C}) having a survival time
Yg following an exponential distribution with parameter θg, let the observed survival outcome be
Qg = min(Yg, X,D − R). Further, define Wg = 1 if Qg = Yg, otherwise Wg = 0. Then, the
probability of an event is:
ξg = E(Wg)



















the complement of which provides the probability of censoring, denoted ηg, i.e., ηg = 1−ξg. Details
pertaining to the derivation of ξg can be found in the Supplementary Materials of Liu and Coad.
[54]
With ξg, the exponential ZR RAR ratio of (4.11) can be obtained. Then, estimation of ξg for
the ZR RAR estimator of (4.12) was obtained using the MLE θ̂gi and the arrival time for patient
i enrolled into group g, denoted Agi. With this, the probability of an event for patient i enrolled





















4.1.2 Optimal ZR RAR for Survival Times Following the Weibull Distribution
Exponential survival times assume a constant hazard, which may be unrealistic in practice. [31,32,51,54]
Other, more flexible, distributions that can account for changing hazards over time may be used
for modeling survival times more accurately. One such distribution is the Weibull distribution, a
log-location-scale family distribution.
Suppose survival time Y follows a Weibull distribution with shape parameter α and scale pa-











for α, β > 0 and y > 0, else fY (y) = 0. Then log(Y ) has an extreme value distribution (EVD) with
shape parameter m = log(β) and scale parameter k = 1/α. In this case, where the observed group-
specific survival outcome is Qg = min(Yg, X,D − R), let Sg = log(Qg). Consider the independent
random sample (si, εi), i = 1, · · · , n, where si represents the survival time for patient i when εi = 1
and the censor time when εi = 0. Then, the likelihood function of m and k is:


























and the loglikelihood function is:
log{`(m, k|s, ε)} = −rlog(k) +
n∑
i=1
{εizi − exp(zi)}, (4.17)
where r =
∑n
i=1 εi, as defined previously, and zi = (si −m)/k, following the standard EVD, i.e.,









{εi − exp(zi)} = 0, and, (4.18)
∂
∂k






{εi − exp(zi)}zi = 0. (4.19)
The approximate variance of the MLE for m, m̂, which corresponds to the Weibull scale parameter









Estimation of the probability of an event, ξ, is far more intricate in the case of survival times
following the Weibull versus the exponential distribution. [25,54] Therefore, Zhang and Rosenberger
and others suggest using the simple nonparametric estimator of the group-specific mean number of
events for construction of the RAR ratio.
Allow the average hazard to be expressed as the reciprocal of the mean survival time as in
the exponential case, i.e., 1/E(S), where E(S) = emΓ(1 + k), where Γ(x) represents the gamma
function such that Γ(x) = (x−1)! when x is an integer. Then, the ZR RAR ratio can be constructed
based upon the comparison of treatment groups with respect to their average hazards. Consider
two independent censored random samples from the previously-described survival distribution,
{(sgi, εgi); g ∈ {T,C}; i = 1, · · · , ng}. Then the optimization problem to minimize the total





































exp(−mT )/Γ(1 + kT )
]1/2 (4.23)
for survival response data having survival times that follow the Weibull distribution. With this, the
probability of response-adaptively allocating patient i+ 1 to the treatment group based on survival


















exp(−m̂T i)/Γ(1 + k̂T i)
]1/2 . (4.24)
4.2 Motivation: Limitations of the Conventional ZR Approach
When RAR is performed using the ZR RAR ratio provided in (4.12) and observed survival times
do, in fact, follow the exponential distribution, then the RAR ratio is said to be correctly-specified.
The same is true of observed survival times following the Weibull distribution undergoing RAR
using the ZR RAR ratio provided in (4.24).
Correctly-specified ZR RAR is illustrated in Figure 4.1. Here, 1,000 patients are response-
adaptively randomized into a simulated RCT where patients survival times followed either the
exponential or Weibull distribution, where 20% of patient responses were censored. Response-
adaptive randomization was performed using the corresponding ZR RAR provided in either (4.12)
or (4.24). Each simulated RCT was replicated 1,000 times, and the resulting 1,000 ZR RAR
ratios for each of the 1,000 patients were averaged to create a single mean observed ZR RAR for
that patient. Correctly-specified ZR RAR was evaluated for two effects sizes based on the hazard
ratio (HR) between treatment groups: the null effect size (HR = 1.0) and the large effect size
(HR = 1.5). For a null effect size, the expected RAR ratio was 0.5; and for a large effect size, the
expected RAR ratios were 0.662 and 0.700 when treatment-specific survival times were simulated
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Figure 4.1: Mean of ZR RAR ratios with 95% CI with correctly-specified sur-
vival times for null and large treatment differences.
to follow the exponential and Weibull distributions, respectively. Specific details pertaining to
simulation construction and data generation, including the parameter values used to target each
effect size, are provided later in this chapter. As evidenced by Figure 4.1, when survival times
are correctly-specified, regardless of effect size or response distribution, RAR performed using the
correct ZR RAR ratio produced randomization results matching those intended by the trial design.
Figure 4.2 indicates how well the ZR RAR ratio maintained the ethical objective of the trial
based on the simulated survival outcome response data. Per the ZR construct, the ethical objective
of interest is the minimization of the total expected hazard of the trial. Details pertaining to the
estimation of the observed and expected objective functions are discussed later in this chapter, but
percent-differences closer to zero indicate that randomization is adhering to the ethical design of the
trial, as intended by the trial design. When correctly-specified, ZR RAR appeared to adequately
minimize the total expected hazard of the trial in all cases with percent-differences near zero, though
some deviation (approximately 10%) was observed when survival times followed the exponential
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Figure 4.2: Percent-difference between the observed and expected ethical ob-
jective function of correctly-specified survival times for null and large treatment
differences using ZR RAR.
distribution and a large treatment effect was observed (Figure 4.2).
Although ZR remains the convention for RAR designs for RCTs with survival outcomes, two
flaws to the ZR RAR design were identified in the present work. First, the ZR RAR approach
relies upon the parametric specification of survival times. Clinical data rarely follow a prescribed
distribution. [55] Thus, imposing a parametric definition in practice may induce misspecification
error, leading to bias in the RAR ratio, exemplified when survival times are assumed to follow
the exponential distribution yet observed patient survival times follow another distribution, e.g.,
Weibull, or are nonparametric. Second, the ZR RAR allocation rules for parametrically-distributed
survival outcomes given in 4.12 and 4.24 can be expressed using the group-specific hazard, defined
as the reciprocal of the distribution-specific mean, and the group-specific SDs of the distribution-
specific scale parameter. Selecting the SD of the distribution-specific scale parameter as a proxy
measure of the variability of the hazard may result in randomization results drastically different
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from those intended irrespective of whether or not survival times are correctly specified.
Figure 4.3: Mean of ZR RAR ratios with 95% CI with misspecified survival
times for null and large treatment differences.
Figure 4.4: Percent-difference between the observed and expected ethical ob-
jective function of misspecified survival times for null and large treatment dif-
ferences using ZR RAR.
92
Figure 4.3 demonstrates the effects of misspecification on the ZR RAR ratio. Simulated trials
were designed as described previously except misspecification was induced. That is, patient survival
times simulated to follow the exponential distribution were randomized using the ZR RAR for sur-
vival times assumed to follow the Weibull distribution provided in (4.24). Likewise, survival times
simulated to follow the Weibull distribution were randomized assuming an exponential distribution
as in (4.12). When no treatment difference existed between groups, randomization remained equal.
However, in the presence of a large treatment difference, misspecified ZR RAR ratios for survival
times following both the exponential and Weibull distributions under-randomized patients to the
treatment group, converging at 0.582 (vs. 0.662) and 0.668 (vs. 0.700), respectively. Furthermore,
the misspecified ZR RAR ratio did not adhere to the ethical objective of the trial (Figure 4.4) as well
as when it was correctly-specified (Figure 4.2), as evidenced by the approximately 10% difference
in the observed versus expected objective function for nearly all scenarios when misspecified.
Misspecification of the ZR RAR ratio may lead to randomization characteristics different from
those intended by the trial design. Thus, the two potential drivers of misspecification of the ZR
RAR described previously motivated the development of a RAR ratio that (i) does not rely upon the
parametric definition of survival times and (ii) obtains measures of the hazards and the variability
thereof directly, as opposed to using proxy measures.
4.3 Optimal RAR Based on the Cumulative Hazard
The aim of the present chapter was to construct a RAR ratio for survival data based on the cumu-
lative hazard such that survival times need not adhere to any specific parametric assumption and
the measure of the variance of the hazard can be estimated directly. This cumulative hazard-based
RAR ratio, denoted H-RAR, is constructed using the group-specific cumulative hazard estimated
at time ω, denoted Hg(ω), and the variance thereof, denoted V ar(Hg(ω)). With this, adhering to
the optimal RAR framework constructed by ZR as explained in Appendix A.5, the H-RAR method
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of optimal randomization sought to minimize the total cumulative hazard of the trial at a given




nT HT (ω) + nC HC(ω)
}
, (4.25)







Taking SD(Hg(ω)) = V ar(Hg(ω))





SD(HC(ω)) HT (ω)1/2 + SD(HT (ω)) HC(ω)1/2
. (4.27)
With this, the probability of randomizing patient i + 1 to T based on information obtained from




SD(HCi(ω)) HT i(ω)1/2 + SD(HTi(ω)) HCi(ω)1/2
. (4.28)
Basing this RAR ratio on the cumulative hazard was done so that a parametric definition for
survival times was not required. However, this RAR ratio could be used in the case of survival
times being assumed to follow a specified parametric distribution. In this case, MLEs of the
distribution-specific parameters would be obtained and used to estimate the distribution-specific
Hgi(ω). The variance thereof may be obtained using the delta method.
[24] Though the H-RAR is
applicable to either parametric or non-parametric survival times, it was of-interest not to assume
a parametric distribution in the present work. Therefore, Hgi(ω) and the variance thereof were
estimated empirically. It should be noted, however, that if a parametric assumption was made
for the survival times, and this assumption was correct, the resulting variance of the estimated
cumulative hazard would be equal to or smaller than the empirically-estimated value.
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Empirical estimation of the cumulative hazard and its variability can be obtained in many ways,
for example, by HEFT estimation or via transformation of the Kaplan-Meier survivor function. [34,39]
In the present chapter the Nelson-Aalen estimator was employed to demonstrate randomization
using H-RAR, selected for its simplicity versus other methods and its ability to produce an estimate
from a small number of events. [32] The Nelson-Aalen empirical estimator of the cumulative hazard
function, denoted HNAgi (ω), and its variance, denoted V ar(H
NA













where εgi and γgi respectively represent the group-specific number of events having occurred and
the number of patients still at-risk among the first i patients enrolled into the trial until a specified
time ω. [32] Using these definitions of HNAgi (ω) and V ar(H
NA
gi (ω)), the variance constraint given in
(4.26) was modified slightly in order to maintain the ZR optimal RAR construct. That is, defining
v(HNAgi (ω)) = ng × V ar(HNAgi (ω)), then taking V = 1:
V ar(HNATi (ω)) + V ar(H
NA








Then, letting SD(HNAgi (ω)) = v(H
NA
gi (ω))














4.3.1 H-RAR Performance Assessment
Performance of the H-RAR was assessed by comparison to the ZR convention. This was done in
three ways. The first assessment compared the behavior of the H-RAR ratio against that of the
ZR RAR ratio when survival times were correctly-specified. In this case, ideally, trends in H-RAR
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and ZR RAR matched. Second, H-RAR was compared to ZR RAR when the ZR RAR ratio was
misspecified using the well-behaved and -understood exponential and Weibull distributions. Finally,
of-interest was the behavior of the H-RAR ratio compared to the conventional ZR RAR ratio when
the ZR RAR ratio was severely misspecified using the exponential change-point hazard (ECPH)
distribution. Ideally the H-RAR behaved as intended by the trial design.
4.3.1.1 Exponential Change-Point Hazard Distribution
Change-point hazard functions are commonly used in survival analyses due to their simplicity,
flexibility, and ability to model complex time-to-event patterns. [55] Consider the following piecewise
constant hazard function of λ(y) of time y ∈ (0, ζ] with P discrete values such that:
λ(y) = λp, ζp−1 < y ≤ ζp (p = 1, · · · , P ), (4.34)
where 0 = ζ0 < ζ1 < · · · < ζp = ζ specify P time intervals in (0, ζ]. Consider n observations
from this model. For the ith (i = 1, · · · , n) observation, let yi (yi ≤ ζ) denote the survival time
when the event indicator εi = 1 or the censor time when εi = 0. In order to discern the likelihood
of an observed outcome, the data pair (yi, εi) generated by the observed survival time and event
indicator must be segmented into P intervals:
yip =

0, yi ≤ ζp−1
yi − ζp−1, ζp−1 < yi ≤ ζp
ζp − ζp−1, yi > ζp
, and εip = εi 1{ζp−1 < yi ≤ ζp} (4.35)
for p = 1, · · · , P , where 1{·} is the indicator function with the value 1 if the inequality is met and
0 otherwise. The vectors (yi1, · · · , yip)′ and (εi1, · · · , εip)′ are the decompositions of yi and εi into
the P time intervals;in particular,
∑P
p=1 yip = yi and
∑P
p=1 εip = εi. Then the likelihood function
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can be expressed as:



























For the present scenarios, survival outcomes having survival times following the ECPH distribu-
tion were segmented into three time intervals, P = 3, such that {ζ0, ζ1, ζ2, ζ3} = {0.0, 0.2, 0.3, D}
for both groups. With this, the cumulative hazard may be expressed as:
H(yi) =

λ1yi, 0 ≤ yi < ζ1
λ1ζ1 + λ2(yi − ζ1), ζ1 ≤ yi < ζ2
λ1ζ1 + λ2(ζ1 − ζ2) + λ3(y − i− ζ2), ζ2 ≤ yi < ζ3
(4.39)
In the present work, λ(yp,g,i) and H(yp,g,i) represent the group-specific (g ∈ {T,C}) hazard and
cumulative hazard, respectively, estimated over time interval p (p = 1, · · · , P ) based on survival
outcomes observed from the first i patients enrolled into the trial. Thus, these estimators (λ(yp,g,i),
H(yp,g,i), and SD(λ(yp,g,i))) were used to construct the RAR ratios for the ECPH distribution based
on the piecewise-hazard function for comparison to the ZR RAR and based on the cumulative hazard
for comparison to H-RAR. Results were used to discern an appropriate tuning value, discussed in
later sections.
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4.3.1.2 Tuning of the Optimal RAR Ratio Based on the Treatment Difference
The optimal ZR design for survival outcomes detailed here does not offer a mechanism for directly
tuning the resulting distribution-specific optimal RAR ratios toward a desired ratio once a desired
treatment effect is observed. Biswas and Bhattacharya modified the ZR RAR ratio for clinical trials
producing continuous response data by including a tuning parameter, τ , as defined in previous
chapters, on the group-specific means in order to target a prespecified randomization ratio, ρ0,
when a desired treatment effect was observed. [6,7] This procedure is detailed in Chapter 1. Prior
to the present work, tuning has not been directly implemented in optimal RAR ratios intended for
use in clinical trials with survival outcomes.





where λg0 for g ∈ {T,C} represents the group-specific measure of the hazard, be it the reciprocal
of the mean as in the ZR parametric cases or a function of the cumulative hazard as in the H-RAR
case. Then, using an approach similar to the framework particularized in Section 1.3.1, tuning of
the survival RAR ratio was achieved by raising λg0 to the τ
th power. To demonstrate this, consider
a generalization of the survival RAR ratio based on λg0 where SD(λg0) represents the measure of
variability used to construct the ratio, e.g., the SD of the scale parameter in ZR RAR or a function
of the variance of the cumulative hazard when using H-RAR. Then, when tuned, the exponential
and Weibull ZR RAR ratios provided in (4.11) and (4.23), respectively, and the H-RAR ratio in































In practice, when used to randomize patient i+ 1 into the trial, the estimators of the survival RAR




















































for exponential ZR RAR, Weibull ZR RAR, and H-RAR, respectively. It was of-interest in the
present work to evaluate and compare the behavior of each of these optimal RAR ratio estimators
when survival times followed various response distributions.
4.4 Evaluation of H-RAR Performance
A simulation study was performed as a means of measuring the bias, precision, and ethicality of
the ZR RAR and empirical H-RAR ratios. For all scenarios, the means and 95% CI of the ZR
or H-RAR ratios averaged over 1,000 simulated trials were plotted with respect to the RAR ratio
intended by the trial design, denoted ρd. When tuned, the intended RAR ratio was 1:1 (ρd = 0.5)
when group-specific survival outcomes were generated to reflect no treatment difference (HR = 1.0)
and 3:1 (ρd = ρ0 = 0.75) when a large treatment difference was generated (HR = 1.5).
[32] Means
of the averaged RAR ratios over 1,000 simulated trials were plotted to measure bias such that
smaller distances from ρd represented less bias, and, thereby, suggested that that RAR ratio more
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accurately enrolled patients into the trial according to the trial design. Precision was measured
using the 95% CI about the mean of the averaged RAR ratios such that CI not containing ρd
may suggest that these RAR ratios produce power-versus-ethics dynamics that differ from those
intended by the trial design.
Adherence to the ethical objective of the RAR design was measured using the plot of the
percent-difference between the observed and expected ethical objective function (%O-E). If the
RAR ratio under investigation adhered to the ethical objective of the trial, the observed ethical
objective function should match the intended ethical objective function. With this, RAR ratio
estimators producing smaller absolute %O-E (i.e., closer to zero) performed best according to this
metric. Details pertaining to the calculation of the %O-E per each of the three H-RAR performance
assessments are discussed in the following section. Finally, type I error was evaluated using the
Z-score introduced by Zhang and Rosenberger for each of the exponential or Weibull survival times
based on observed survival responses from the first 500 participants enrolled into the simulated
trials where no treatment effect was generated (HR=1.0).
4.5 Simulation Details
All simulated trials enrolled 1,000 patients. When the RAR ratio under investigation was the ZR
RAR ratio constructed using Weibull parameters, simulated trials were performed over 1,500 repli-
cates. Otherwise, 1,000 replicates were performed. This difference was due to greater complexity
of moment estimation for the Weibull ZR RAR versus the exponential ZR RAR or H-RAR, and
its impact on the size of the lead-in group prior to the initiation of RAR. Additional details are
discussed later in this chapter.
The treatment group was considered superior to the control group when a large treatment
difference existed. As such, survival outcomes observed from the treatment group were generated
to reflect longer survival times, thus corresponding to a lower hazard of experiencing an event.
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Table 4.1: Distribution-specific parameter values for simulation of treatment and control group
survival outcomes by effect size where trial recruitment time R = 85/85 = 1 and trial duration
D = 100/85 ≈ 1.176.
Survival 20% Censoring
Times Parameter Control/Null HR Large HR
Expo- Mean/Scale, θg0 0.189 0.283
nential Hazard, λg0 5.292 3.528
SD of scale, SD(θg0) 0.211 0.339
Intended censoring, ηg0 0.200 0.299
Intended ρd without τ 0.500 0.662
τ for 3:1 using ZR RAR 3.093 3.093
τ for 3:1 using H RAR 3.625 3.625
Weibull Shape, αg0 3.500 2.000
Scale, βg0 0.128 0.195
EVD scale, kg0 0.286 0.500
EVD location, mg0 -2.058 -0.711
Mean, θg0 0.115 0.172
Hazard, λg0 8.700 5.800
Intended censoring, ηg0 0.800 0.700
Gg0
∗ 1.449 1.716
SD Weibull scale, SD(mg0) 0.344 0.655
Intended ρd without τ 0.500 0.700
τ for 3:1 using ZR RAR 2.242 2.242
τ for 3:1 using H RAR 3.700 3.700
∗E(zez)=0.423, E(z2ez)=0.827 ∀ g
Expo- Hazard over (ζ0, ζ1]
∗, λ1,g0 7.000 4.667
nential Hazard over (ζ1, ζ2]
∗, λ2,g0 30.000 20.000
Change- Hazard over (ζ2, ζ3]
∗, λ3,g0 5.000 3.333
Point Intended censoring, ηg0 0.800 0.750
Hazard τ for 3:1 using ZR RAR 11.000 11.000
τ for 3:1 using H RAR 3.963 3.963
∗ζ0=0.0, ζ1=0.2, ζ2=0.3, ζ3=D ∀ g
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Control group survival outcomes where survival times followed an exponential distribution with
mean parameter θC0 were developed as follows. First, the recruitment time and trial duration
parameters were fixed as R and D, respectively, and the desired probability of event, ξC0, taking
the value 0.8 to reflect 20% censoring was used in (4.14) to obtain θC0. The hazard of the control
group, λC0, was obtained by taking the reciprocal of the mean parameter. The resulting SD of the
control group mean, SD(θC0), was obtained using θC0/
√
ξC0. Next, the hazard of the treatment
group, λT0, was obtained by dividing the control group hazard by the desired HR (either 1.0
or 1.5). Then, the treatment group mean, θT0, was found by taking the reciprocal thereof, i.e.,
1/λT0. Fixed R and D and θT0 were used to obtain ξT0 using (4.14) and SD(θT0). With this, all
parameters necessary to derive the exponential survival times reflecting varying treatment difference
and censoring probabilities were calculated. Table 4.1 contains the specific values for each of these
parameters, as well as those for the subsequently-described Weibull and ECPH survival times.
Simulations wherein survival times following the Weibull distribution were derived were more
involved. First, the Weibull shape parameter for the control group, αC0, was selected. Then, a
simulation of 1,000 replicates with 1,000 patients was performed in order to select the Weibull scale
parameter, βC0, that produced the desired ξC0. Because Weibull survival times are log-transformed
for ZR RAR, the EVD parameters corresponding to each Weibull parameter was obtained: the
EVD scale parameter, kC0, was obtained by taking the reciprocal of αC0 and the EVD location
parameter, mC0, was obtained by taking the logarithm of βC0. The mean control group survival
time was defined as θC0 = exp(mC0)Γ(1 + kC0), the reciprocal of which provided the hazard of the
control group, λC0, as defined by Zhang and Rosenberger. To find the variance of these survival
times, the quantities E(ziexp(zi)) and E(z
2
i exp(zi)) were obtained in R by numerically integrating
zf(z) and z2f(z), respectively, from 0 to 75. These values were held constant for both the control
and treatment groups, and were used along with ξC0 to obtain GC0. With this, SD(mC0), the SD
102
of the control group EVD location parameter (corresponding to βC0 was obtain by kC0 ×
√
GC0.
The hazard of the treatment group, λT0, was obtained by taking the ratio of the λC0 and HR,
and the mean survival time, θT0, was the reciprocal thereof. Upon selecting the Weibull shape
parameter for the treatment group, αT0, the Weibull scale parameter for the treatment group
was obtained using the Weibull expression of the mean such that, βT0 = θT0/Γ(1 + 1/αT0). The
probability of an event occurring in the treatment group, ξT0, was discerned by generating 1,000
iterations of survival outcome data having Weibull survival times with parameters αT0 and βT0 for
1,000 recruited patients. The mean of the sum of events scaled by 1,000 provided the expected ξT0.
The treatment group location and scale parameters for the EVD, mT0 and kT0, respectively, were
obtained, and GT0 was estimated using the previously fixed E(ziexp(zi)), E(z
2
i exp(zi)), and ξT0
such that SD(mT0) was obtained.
Finally, change-points and hazards parametrizing survival times following the ECPH distribu-
tion for the control group were selected using the cpsurvsim::exp cdfsim in R. [55] These param-
eters were selected such that the desired censoring probability was observed over 1,000 replicated
datasets enrolling 1,000 patients. Change-points were held constant for both groups so that the
assumption of proportional hazards could be maintained within time intervals. This allowed for the
obtainment of the interval-specific treatment group hazards by dividing the interval-specific control
group hazards by the intended HR. A simulation was performed where 1,000 replicates of 1,000
patients whose survival outcomes consisted of survival times that followed the ECPH distribution
parametrized according to the interval-specific treatment group hazards and their corresponding
change-points. The censoring probability was discerned by taking the complement of the number
of observed events scaled by 1,000, the number of replicated trials.
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4.5.1 Survival Data Generation
It was shown by Zhang and Rosenberger and Hu and Zhang that a moderate delay in censored
survival responses had only a marginal effect on the asymptotic properties of these RAR proce-
dures. [6,8] Therefore, survival responses were artificially treated as immediate during the simulation
process, mimicking the simulation design of others. [8,25,54] It is worth noting that relying on these
asymptotic properties is a reasonable assumption for short-term survival outcomes, but not when
measuring survival in terms of months or years. The immediate measure assumption may no longer
be valid in such scenarios because there would be a high level of censoring at the beginning of the
trial. Without having observed an event, there would not be enough survival information to initiate
RAR estimation, as such, the asymptotic assumptions would fail.
General survival data derivation and the censoring scheme employed in the present simulation
were based on the Rosenberg and Seshaiyer dynamic discussed in Section 4.1.1.1. Trial details were
based loosely on the motivating example of Jones et al., explored in both Zhang and Rosenberger
and Liu and Coad. [15,25,54,56] This was a phase III clinical trial comparing docetaxel and paclitaxel,
two drugs approved for use in patients with metastatic breast cancer, where docetaxel showed more
favorable chemical and biological outcomes than paclitaxel. With this, it would be ideal to allocate
as many patients to the docetaxel group as possible. For this reason, the docetaxel group was
considered the treatment group and the paclitaxel group was the control. As in both Zhang and
Rosenberger and Liu and Coad, though Jones et al. conducted the trial at multiple sites, RAR was
assumed to be centralized in the present simulation.
Where an event was defined as either tumor progression, unacceptable toxicity, or consent with-
drawal, the ideal survival outcome was censoring due to having completed the study having neither
experienced any of the previously-described events nor being censored for any other reason result-
ing in a trial participant being lost-to-follow-up. Therefore, it was hypothesized that the docetaxel
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group would have a larger censoring probability than the paclitaxel group. The recruitment time
of the Jones et al. docetaxel-versus-paclitaxel trial was 84 months and the duration of the trial
was 102 months. For the present simulation, these values were rounded to reflect a recruitment
time of 85 and trial duration of 100. As in Zhang and Rosenberger, since the ZR RAR ratios are
not dependent upon the unit of the parameters of interest, the recruitment time and trial duration
parameters were scaled by the recruitment time, i.e., R = 85/85 = 1 and D = 100/85 ≈ 1.18. [25,54]


























The arrival time for a given patient and the trial duration start from the beginning of the study,
whereas the survival time and censor time commence from the arrival of that patient (Part A of
Figure 4.5). At the patient level, a random sample of arrival times following U [0, 1] were generated
for N×2 (N patients in two treatment groups) recruited patients, then sorted into ascending order.
Independently, N × 2 initial censor times were generated using U [0, D]. Observed patient censor
times were then the sum of that patient’s arrival time and initial censor time. [25,54]
To aid in the construction of the lead-in (details in next section), the first pair of arrival and
observed censor times were assigned to the control group, then the second pair to the treatment
group, and so forth following this pattern until N arrival and observed censor times were assigned to
each group. By group, initial survival times were generated and summed with their corresponding
arrival times to produce the observed survival time. [25,54] Finally, the observed survival outcome
times for a given patient was the minimum of that patient’s observed survival time, observed censor
time, and the length of time that that patient was in the study, represented by the difference between
D and that patient’s arrival time. [25,54]
4.5.2 Lead-in Simulation Process
As discussed in previous chapters, lead-ins are necessary in response-adaptive CTs because RAR
assigns patients according to already-observed response data. [3,6,7,25,54] Therefore, the present sim-
ulation followed the work of Liu and Coad by using the permuted-block design to construct the
lead-in from which RAR would begin. [54] A block-size of one (i.e., alternating allocation) was used
to ensure the fewest number of patients were equally-randomized into the trial during the lead-in
period. Part B of Figure 4.5 demonstrates the lead-in process used in the present simulation study.
The ZR RAR ratios are based on the parameters of the assumed survival time distributions.
Therefore, for a more stable start to MLE estimation, the present simulation designated that the
lead-in period consist of at least three observed survival outcomes, meaning either an event or
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Table 4.2: Percent-convergence at three observed survival outcomes per group
and median lead-in sizes per simulated RCT scenario.
20% Censor Exp ZR RAR: Weibull ZR RAR: H-based RAR:
Survival %conv (median) %conv (median) %conv (median)
HR Times Not tuned Tuned Not tuned Tuned Tuned
1.0 Exp 100.0 (72) 100.0 (72) 99.6 (72) 99.7 (72) 100.0 (72)
Weibull 100.0 (134) 100.0 (134) 99.8 (132) 100.0 (136) 100.0 (136)
ECPH 100.0 (64) 97.2 (64) 100.0 (64)
1.5 Exp 100.0 (78) 100.0 (76) 99.0 (78) 99.7 (78) 100.0 (78)
Weibull 100.0 (128) 100.0 (128) 99.8 (128) 99.7 (128) 100.0 (130)
ECPH 100.0 (70) 98.3 (72) 100.0 (70)
%conv: percent of trials with all patients randomized; Exp: Exponential; ECPH: Exponential
change-point hazard
censor time beyond censoring for the reason that the subject was still participating in the study
was observed. At least one of these observed survival outcomes must have been an observed survival
time. Three observed outcomes was selected for the initiation of RAR because this was the smallest
number of observations to begin variance estimation. Table 4.2 demonstrates that, across scenarios,
greater than 98% of simulated trials were successful, where simulated trials were deemed successful
when all 1,000 patients were randomized into the trial following at least three observed survival
outcomes during the lead-in period. The resulting median lead-in sizes per scenario are provided
in Table 4.2, as well. To account for sequentially-increasing arrival times (i.e., staggered entry),
the number of occurrences where the observed survival outcome for patients one to i − 1 were
greater than the arrival time for patient i were counted, beginning with the second patient in each
group. The patient number i at which it first occurs that at least three survival outcomes have
been observed, one of which was an event, was recorded as the lead-in size for each group. Then,
the trial lead-in size, L, was taken as the maximum of the two group-specific lead-in sizes.
4.5.3 RAR for Simulated RCT with Survival Outcomes
Following the generation of data (§4.5.1) and the determination of the lead-in group (§4.5.2), RAR
was initiated via the randomization of patient L+1 (Part C of Figure 4.5). Before MLE estimation
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could begin, two options for patient L+ 1 were considered. These two options were characterized
as the first patient in each group whose arrival time was greater than the arrival time belonging
to the final patient enrolled during the lead-in, or patient L. Thus, two sets of survival data were
created where both were comprised of the arrival and observed survival outcome times collected
during the lead-in period, but where one dataset appended the first applicable record for patient
L + 1 from the control group, and the other from the treatment group. For each group-specific
set of survival data, any lead-in patients’ observed outcome survival times that were greater than
the arrival time for patient L+ 1 (i.e., the maximum arrival time) were reset to be the maximum
arrival time per patient L + 1. With this, MLE estimation at the time of enrollment for subject
L+ 1 could be performed.
Two additional variables were created in order to execute MLE estimation. First was an indi-
cator variable taking the value of one when the observed survival outcome time for a given patient
is that patient’s survival time. Second was information time, the difference between each patient’s
observed survival outcome time and the arrival time for that patient. Maximum likelihood esti-
mation was performed using information time and the event indicator at the patient level. These
estimates were used to construct the RAR ratio under investigation for that simulation. The re-
sulting RAR ratio was compared to a uniform random variate using U(0, 1) such that patient L+1
was randomized to the treatment group if the estimated RAR ratio was greater than the uniform
random variate. If group assignment was treatment, the survival data belonging to patient L + 1
from the treatment group was appended to the lead-in survival data as a part of the overall trial
response data. Put another way, the dataset reflecting the lead-in survival data and the survival
information for patient L+ 1 from the treatment group becomes the set of survival data resulting
from the simulated trial thus far, containing the survival data upon which the randomization of
patient L+ 2 will be based. The same is true of the control group survival data if the RAR ratio
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was less than the uniform random variate. This process was repeated until all N patients were
enrolled into the trial. This particular approach was taken in an effort to mimic staggered entry
into the trial where the arrival time of a given patient i was always greater than the arrival time
of patient i− 1, regardless of group affiliation.
To produce the previously-described plots of the means and 95% CIs, the RAR ratios across
1,000 iterations of each of the ZR RAR vs. H-RAR scenarios considered were collected for each
of the 1,000 patients enrolled. The means and variances of these sets of 1,000 RAR ratios were
calculated and 95% CIs were constructed. The ethical objective of RAR in these trials was to
minimize either the total expected hazard or mean cumulative hazard of patients enrolled into
the trial. Therefore, to construct the plot of the %O-E, group-specific sample sizes and hazards
or cumulative hazards were collected after the enrollment of each patient. Their means were then
calculated across 1,000 trials.
Table 4.3: Observed versus expected hazard or cumulative hazard for estimation of percent-
difference (%O-E) in ethicality of RAR by scenario.
Survival
Scenario Times RAR Observed Expected
1: Correct Exp Exp ZR λ̂gi = 1/θ̂gi λg0 = 1/θg0










ification Weibull Exp ZR λ̂gi = 1/θ̂gi λg0 =
exp(−mg0)
Γ(1+kg0)
3: H-RAR Using Exp H-RAR ĤNAgi (y) of (4.29) Exp Ĥ
E
gi(y) = yg/θ̂gi
Nelson-Aalen Weibull H-RAR ĤNAgi (y) of (4.29) Weibull Ĥ
W
gi (y) = (yg/β̂gi)
α̂gi
The simulation design varied for each of the simulation scenarios, as did the estimation of the
%O-E. Borrowing the general notation introduced in Section 4.3.1.2, the ethical objective functions








With this, the observed, Oi, and expected, Ei, ethical objective functions were defined as:
Oi = n̂T i λ̂Ti + n̂Ci λ̂Ci, and, (4.47)
Ei = E(nT i) λT0 + E(nCi) λC0, (4.48)
where ¯̂ngi and E(ngi) were defined as in Section 2.2, and
¯̂
λgi represents the mean observed hazard
or cumulative hazard of group g from the first to the ith patient enrolled into the trial, averaged
over 1,000 simulated trials. In most cases, λg0, the expected group-specific hazard or cumulative
hazard, was constant, determined by parameter values set at the start of the simulation. However,
when RAR was performed using H-RAR, λg0 was the cumulative hazard estimated for each patient
enrolled into the trial and averaged over 1,000 trials. This is described more fully by scenario in
Table 4.3. With this, the percent-difference between the observed and expected ethical objective
of the trial is defined as in (2.35), i.e., %O-E = 100× (Oi − Ei)/Ei.
4.6 Randomization Results
Results for simulated RCTs with survival outcomes are discussed in what follows. All curves were
loess-smoothed using a bandwidth of 0.15. As discussed in Section 4.3.1, the performance of the
H-RAR was assessed in comparison to ZR RAR when survival times were (a) correctly-specified,
(b) incorrectly-specified, and (c) followed neither the exponential nor Weibull distribution. When
tuned and correctly-specified, randomization using the ZR RAR ratio behaved precisely as intended
by the trial design. That is, mean randomization converges to 3:1 when a large HR is observed and
stays at 0.5 when an HR of 1.0 is observed (Figure 4.6), and the ethical objective of the trial is well-
maintained (Figure 4.7). When misspecified, save for the null case where randomization remains
equal, the previously-described behavior changes. As opposed to converging to the intended 3:1
randomization ratio (Figure 4.8, green curve), patients are over-randomized to treatment (0.808)
when survival times followed the exponential distribution but patients were randomized into the
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Figure 4.6: Mean of ZR RAR ratios with 95% CI with correctly-specified sur-
vival times for null and large treatment differences when tuned to target desired
3:1 ratio.
Figure 4.7: Percent-difference between the observed and expected ethical ob-
jective function of correctly-specified survival times for null and large treatment
differences using ZR RAR when tuned to target desired 3:1 ratio.
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Figure 4.8: Mean of ZR RAR ratios with 95% CI with incorrectly-specified
survival times for null and large treatment differences when tuned to target
desired 3:1 ratio.
Figure 4.9: Percent-difference between the observed and expected ethical objec-
tive function of incorrectly-specified survival times for null and large treatment
differences using ZR RAR when tuned to target desired 3:1 ratio.
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trial using the Weibull ZR RAR ratio (grey curve). By contrast, when the opposite was true
(red curve), patients were under-randomized to treatment (0.618). When survival times followed
the Weibull distribution but were randomized using the exponential ZR RAR ratio, the ethical
objective of the trial was not always maintained (Figure 4.9, red and blue curves).
Figure 4.10: Mean of H-RAR ratios with 95% CI for null and large treatment
differences when tuned to target desired 3:1 ratio.
Table 4.4: Assessment of type I error using the ZR-defined Z-score for exponen-
tial and Weibull survival times based on observed survival information from first
500 participants enrolled into the simulated trial when no treatment difference
existed (HR=1.0) across 1,000 simulated trials.
Truth RAR Z-score (ZR) p-value
Exponential Exponential -0.001 0.9499
Weibull 0.002 0.9952
H-RAR -0.002 0.9105
Weibull Exponential 0.000 0.9771
Weibull 0.002 0.9614
H-RAR 0.002 0.9981
Randomization using the H-RAR method (Figure 4.10) converged to 3:1 randomization, both
behaving in a manner similar to the ZR RAR conventional approach when correctly-specified (Fig-
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Figure 4.11: Percent-difference between the observed and expected ethical ob-
jective function of H-RAR for null and large treatment differences when tuned
to target desired 3:1 ratio.
Figure 4.12: Mean of H-RAR ratios with 95% CI for a large treatment difference
when tuned to target desired 3:1 ratio.
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ure 4.6) and outperforming the same when misspecified (Figure 4.8). When a large treatment
difference was observed and survival times followed the Weibull distribution (red curve), ZR RAR
more closely adhered to the trial design in samples less than approximately 500 patients when
correctly-specified and between approximately 250 and 400 patients when misspecified. Nonethe-
less, H-RAR adhered to the ethical objective of randomization than ZR RAR regardless of distribu-
tional specification (Figure 4.11). Finally, when survival times followed neither the exponential nor
the Weibull distributions and were tuned to target 3:1 randomization (Figure 4.12, brown curve),
H-RAR most closely adhered to randomization desired by the trial design than did either of the
knowingly-misspecified ZR RAR ratios (blue or red curves). Finally, as evidenced by Table 4.4, no
erroneous treatment differences were observed.
4.7 Discussion
Response-adaptive randomization based on the cumulative hazard presents as a viable alternative
to the conventional optimal RAR approach set forth by Zhang and Rosenberger for survival out-
comes. [25] However, when fewer than 500 subjects have been enrolled into the trial, ZR RAR is
suggested for the sake of simplicity if the distribution of the survival times is either exponential or
Weibull and known to be correct. If the ethical goal of randomization is the primary focus of the
trial or the distribution of the survival times cannot be assumed as either exponential or Weibull,
H-RAR may be the most appropriate option overall.
In order to compare the H-RAR and the ZR RAR methods, tuning was required. Tuning relied
upon the proportional hazard assumption at 30 days, the time at which the large effect size was
assumed to be observed. Furthermore, the simulation itself was based on the Jones et al. trial
reconstructed in other works discussing RAR with survival outcomes. There were some flaws to
this design, however. As opposed to considering the trial duration (D) a single unit, the trial
recruitment period (R) was the single unit (R = 85/85 = 1 and D = 100/85 > 1). If R were made
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much closer to zero, a shorter lead-in would have been observed, and RAR would have performed




5.1 Misspecification for Continuous Response Data
When designing a clinical trial with continuous response outcomes, most investigators assume that
subject responses are going to follow the normal distribution. Using this normality assumption, ER
is typically employed. Equal randomization is the most powerful type of randomization, requiring
the fewest number of subjects to be enrolled into the trial to discern a clinically-meaningful differ-
ence between group than any other type of randomization. By the time a drug or intervention has
progressed to a phase III clinical trial, there should be very strong evidence supporting its effective-
ness and efficacy over the active control (e.g., standard of care). Therefore, despite its power, in
the context of a phase III clinical trial, ER is unethical because, by definition, approximately half
of all trial participants will be randomized to an inferior treatment group. Thus, RAR should be
used to maintain the power of the trial and ethical treatment of the subjects in the trial by skewing
randomization toward the better-performing treatment group based on responses obtained from
subjects who have already completed their intervention. Because RAR is based upon the mean
and SD of the response distribution of the observed subject responses, it was speculated that the
normality assumption cannot always be justified in small sample.
Therefore, two methods were developed to obtain a RAR ratio robust against distributional
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misspecification, particularly deviations from normality, when response values were continuous
in nature. The first method estimated the RAR ratio using empirical estimation of the CDF
obtained using either the PLKM or HEFT methodologies (Chapter 2). The second method of
obtaining a RAR ratio that is robust to distributional misspecification employed a weighted-average
approach (Chapter 3). With this, a variety of RAR ratios corresponding to a variety of potential
response distributions (e.g., normal, gamma, logistic) were weighted based on how well that response
distribution fit the observed response data. Weights were obtained two ways, using the AIC or KS
metrics, and summed to one. Once the weights and randomization ratios per each candidate
response distribution were obtained, their products are summed.
It was found that, in general, neither the empirical nor the weight-average randomization meth-
ods outperformed randomization under the normality assumption. Nonetheless, the goal of obtain-
ing estimators of the RAR ratio either independent of any distributional assumption or considering
a variety of response distributions was achieved. These estimators were well-behaved with respect
to adhering to and maintaining randomization as intended by the trial design. With respect to
the empirical estimators, in general, HEFT outperformed PLKM randomization, but at the price
of a substantially larger lead-in period, something that is not always practical in real-world trials.
Nonetheless, the results observed in Chapters 2 and 3 pertain only the scenarios investigated herein.
Results may vary for alternative distributions or methods of estimation. Appendices A.28 and A.29
hold examples of the R codes used to simulate the trials in Chapters 2 and 3, respectively.
5.2 Misspecification for Survival Response Data
Little research with respect to RAR has been done in RCTs with survival outcomes. Zhang and
Rosenberger developed an optimal RAR framework for survival outcomes that is convention, but is
insufficient for robust estimation. The ZR RAR approach relies upon the correct distributional spec-
ification of survival times and obtains measures of the hazards and the variance thereof via proxies.
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Accuracy of the distributional assumption is not guaranteed with real-world data. Therefore, the
ZR RAR framework was used to develop an estimator of the RAR ratio for survival outcomes using
the cumulative hazard, the H-RAR (Chapter 4). The H-RAR was shown to be quite flexible and
robust to distributional misspecification of survival times. That is, H-RAR nearly recreated the
correctly-specified ZR RAR and outperformed the misspecified ZR RAR when survival times fol-
lowed either the well-behaved exponential or Weibull response distributions. When survival times
followed a poorly-behaved response distribution, i.e., the ECPH distribution, H-RAR achieved and
maintained randomization as intended by the trial design more quickly than ZR RAR intended
for survival times following either exponential or Weibull survival times (R code for simulated trial
provided in Appendix A.30). Results thus far utilize the most simplistic estimator of the cumulative
hazard function, the Nelson-Aalen estimator. Future work may focus on moving into more complex
estimation methods and considering alternative motivating data beyond the oft-used Jones et al.
trial.
5.2.1 Advantages and Disadvantages of Optimal RAR
There are a number of advantages and disadvantages to employing RAR. [57,58] Advantages to using
RAR center about its ability to balance ethics and power. Optimal RAR is as powerful as the
commonly-implemented ER, but targets an ethical objective. With this, optimal RAR is able to
discern a better treatmet group while participants are being randomized into the trial, such that,
if neither treatment is proving to be superior, randomization simply remains equal. With this,
ideally, participant enrollment will be higher and attrition will be lower because a larger number
of participants are undergoing the better treatment if one is being evidenced.
Disadvantages of the optimal RAR design include its requirement of a lead-in group to be
equally-randomized into the study prior to the initiation of RAR. In some cases, the lead-in period
may be small (e.g., three participants per group). Other times, the lead-in may be quite large,
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depending on the method of optimal RAR being employed. For this reason, RCTs using RAR may
only be advantageous when many participants can be recruited quickly. In this same vein, RAR
should only be adopted when the period of time between participant enrollment and the obtainment
of response information is small. Otherwise, the lead-in period will inherently be extended: a large
number of participants will be enrolled into the trial under ER while the clinical trialists are
waiting to accrue enough results information from those enrolled to begin RAR. Finally, estimation
of the RAR ratio is performed after each subject enrolled into the trial. Such constant estimation
procedures may be computationally and logistically taxing, requiring complex computing methods
and more personnel training − all of which adds financial expense to the trial design.
5.2.2 Limitations and Future Work
In the present work, unimodal response distributions were evaluated for each method. This as-
sumption may not be appropriate for any of these methods. For example, consider the scenario in
which the habits of the medical professionals providing the trial intervention (e.g., training exercise,
medications, etc.) to patients change over time. This is a likely scenario given human behaviors
change over time, without excepting behaviors pertaining to the progress of the RCT. With this,
greater than one mode may be observed from the first to the ith participant enrolled into the tri-
al. Where this is a moderately common occurrence, the assumption of unimodality collapses. [58]
Furthermore, the present work assumed both the treatment and control groups followed the same
response distribution versus situations where the treatment followed one response distribution and
the control response data followed another. This is another distributional assumption that may
not be appropriate.
In future work, the assumptions of distributional unimodality and between-group similarity may
need to be re-addressed. Other limitations to the present work to be addressed in future iterations
include the incorporation of multi-site context, the consideration of participant drop-out or missing
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information, the incorporation of a lag between trial enrollment and response data obtainment.
And, as alluded to previously, alternative estimation methods and/or distributional assumptions
may need to be considered in an attempt to replicate or clarify the results presented herein.
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Appendix
A.1 Link Function-Based Randomization Designs
Response-adaptive randomized designs estimate a treatment difference based on available data. [3]
This treatment difference plays an integral role in the link function, denoted Λ, a function that
maps an estimated treatment difference to the inclusive unit such that a treatment difference of
zero elicits a randomization probability of one-half and mapping is symmetric. [3] If an estimated
treatment difference, d, yields an allocation probability of ρd, then −d should yield an allocation
probability of 1− ρd.
Any CDF that is symmetric about zero would offer a reasonable link function. The normal
and the logistic CDFs are two convenient examples since both have preexisting, well-defined link
functions (the probit link and the logit link, respectively), both are symmetric, and both may be
symmetric about zero by simple manipulation of their respective location parameters.
Under the link function-based design, subject {i+ 1} is allocated to T with probability Λ(µ̂T i−
µ̂Ci) and to C with probability 1 − Λ(µ̂T i − µ̂Ci) = Λ(µ̂Ci − µ̂T i), where µ̂gi is the mean of the
first {1, 2, · · · , i} subjects that were allocated to treatment g. [3] Then, the treatment with the more
desirable responses is favored during randomization.
A.2 Continuous Adaptation of Binary-Outcome Randomization Designs
The Doubly-adaptive Biased Coin Design (DBCD) is a family of RAR schemes designed to achieve a
desired randomization ratio using two arguments, the current allocation ratio as determined by the
treatment responses from subjects who have already completed the trial, and the target allocation
ratio. [1,3,8,9] Though originally conceived for trials evaluating binary outcomes, the DBCD can be
applied for continuous or time-to-event treatment responses. [10]
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In the same vein, the Continuous Drop-the-Loser (CDL) design developed by Ivanova et al. [11] is
an extension of the urn-based, binary Drop-the-Loser design by Ivanova. [12] Under the CDL design,
entering subjects are randomized according to a process based on draws from an urn containing
(B + 1) balls of either type 0 or type b, where b = 1, · · · , B, where B represents the number of
treatments in the trial. If the response to treatment b for subject i exceeds a predefined threshold,
then the type b ball used to allocate subject i is returned to the urn; otherwise, it is removed. Type
0 balls are returned immediately to the urn if drawn, and B balls are added to the urn. Over time,
randomization is skewed toward the superior treatment.
Yao and Wei [13] developed a similar design for time-to-event outcomes called Randomized Play-
the-Winner (RPW). The RPW scheme was shown to randomize more subjects to the better treat-
ment with small loss of power in simulated RCTs where survival times were dichotomized. [13].
A.3 Designs Using Treatment Effect Mapping
Assuming two treatments, Treatment Effect Mapping (TEM) is defined by letting η(·) be a con-
tinuous function that maps from the real line to the inclusive unit, i.e., R 7→ [0, 1], such that
η(0) = 0.5, η(x) > 0.5 for x > 0, and η(x) < 0.5 for x < 0. [14] If ∆ denotes a measure of the true
treatment effect, where ∆̂j is the observed value of ∆ as determined by the treatment responses
obtained from subjects {1, · · · , j}, then the superiority of treatment over control is evidenced by
∆̂j > 0, i.e., η(∆̂j) > 0.5. If ∆̂j = 0, then the two treatments are deemed equivalent.
With this, Rosenberger [14] proposed a RAR design in which subject j is allocated to the superior
treatment with probability η(∆̂j−1), where ∆ is the normalized linear rank test statistic and the
TEM function is given by η(x) = (1 + x)/2. Under this design, if Yi represents the response from
subject i, i = 1, · · · , n, among j responses, j = i, · · · , n, for n subjects total, then, the rank of
Yi is given by Rij , and the score function for Rij is given by aij . After allocating the first two
















, where δj = 1 if subject j was allocated to T , and a
+
ij = aijI(aij > 0), where
I(·) is the indicator function. The values of a+ji for δj = 1 will be larger when subjects in T produce
larger responses than subjects in C, resulting in an elevated probability for subject {i + 1} to be
allocated to T , since larger ranks indicate better responses.
Rosenberger and Seshaiyer [15] also developed a TEM design using the log-rank statistic while
focusing attention on TEM for survival times that were assumed to follow an exponential, Weibull,
and lognormal distribution. Hallstrom et al. [16] utilized TEM using a statistic which is relative to
the proportion of uncensored subjects over all subjects regardless of treatment group affiliation.
This method was found to increase ethical gain, but had little effect on power. [16]
A.4 Wilcoxon-Mann-Whitney Adaptive Design
Let the responses to treatments T and C be real-valued random variables such that YT ∼ F (yT )
and YC ∼ G(yC), ε ∈ [0, 1] is the unknown location shift pairing the CDFs F (yT ) and G(yC) with
the relationship G(yC) = F (yT − ε). The Wilcoxon-Mann-Whitney (WMW) test [18,19] evaluates
the hypothesis H0 : ε = 0 against H1 : ε > 0, where ε ∈ [0, 1] is defined as follows. Define
Zi = εiYT i + (1 − εi)YCi, where Ygi represents the response to treatment g for subject i. Then,
define the score function for Zi as φ(Zi, Zj) = 1 if (Zi > Zj) and (εi > εj), and zero otherwise. The





The FW urn design [20–22] process begins with an urn containing 2α balls, α balls for each
treatment T and C. If a T ball is drawn from the urn, it is immediately replaced and β C balls are
added. Thus, after the first two subjects are equally-allocated, the randomization probability to T





, where Ngi represents the number of times
subjects currently allocated to treatment g. Allocating according to this process [21,22] skews the
urn in favor of the superior treatment. Bandyopadhyay and Biswas [17] bridged these two concepts
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by incorporating the WMW-type [18,19] test statistic W into the FW urn design [20–22], resulting in




A.5 Zhang and Rosenberger Derivation of Optimal RAR Ratio
Let ng be the target sample size for treatment group g, where g ∈ {T,C} such that nT + nC =
N , where N represents the total number of subjects enrolled into the trial, indexed by i (i =
1, 2, · · · , N). As well, let Yg be the responses of patients assigned to treatment group g, where
Yg ∼ N(µg, σ2g). Assuming smaller response values are more desirable, researchers may wish to
minimize the total expected response value observed from patient data, thus-producing the following




























nT µT + nC µC
}
, (1)








for some constant V . The solution of which provides the optimal RAR ratio. To solve:
1. Set R = nT /nC and R
∗ =
min
R {nTµT + nCµC}.
2. Re-write (1) in terms of R to minimize R∗ with respect to R.
(a) Solve R for nT and nC :
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R(N − nT ) = nT
RN = nT (1 +R)
R
1 +R
N = nT (3)






























3. Solve for N by inserting (3) and (4) into (2), then update (5). Biswas and Bhattacharya
suggest taking V = 1 for simplicity and without loss of generality.
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, it is plain to see that nT = σT
√








































A.6 Jennison and Turnbill Design
Assume two treatment groups T and C, where groups are denoted by g, i.e., g = {T,C}, and
group-specific responses have a mean µg and variance σ
2
g . Jennison and Turnbill
[23] developed a
constrained optimal RAR framework assuming treatment variances, σ2g , were known. The goal of









where a is a predetermined constant, δ is the treatment difference for which the study was powered,
and ng is the number of subjects allocated to treatment g. Solving this according to the variance
of the estimated treatment difference in (1.2) gives the following optimal randomization ratio to T :









Atkinson and Biswas [3] identified that, though this designis straightforward, it is based upon a
poorly-defined importance criterion. As a result, it is unclear what the objective function (10) aims
to minimize, damaging design interpretation.
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A.7 Biswas and Mandal Design
For treatments T and C, Biswas and Mandal [5] assumed treatment-specific responses have a mean
µg and variance σ
2




C are assumed to be unknown and smaller responses more
desirable. Furthermore, Biswas and Mandal [5] sought to minimize the total number of responses
greater than an investigator-defined threshold constant, y0. A large-enough response could be
interpreted as a failure. Therefore, the goal of this design is to minimize the total number of






































A.8 Algorithm 1: Trial Generation.
Trial generation:
1. Generate N random variates per group (YT i and YCi, i = {1, · · · , N}).
2. Generate N uniform random variates (ui ∼ U(0, 1), i = {1, · · · , N}).
3. For lead-in period i ∈ {1, · · · , L}, if ui < 0.5, subject response data was YT i, else YCi.
4. For subjects {L+ 1, · · · , N}, obtain estimates for randomization: because smaller responses
are more desirable, if ui < ρ̂, subject responses was YT i, else YCi.
A.9 Algorithm 2: X2U Response Data.
Simulation of X2U response data:
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1. GenerateN random variates per distribution (Xi ∼ χ2(k) and Ui ∼ U(a, b), for i = {1, · · · , N}).
2. Generate N uniform random variates (ui ∼ U(0, 1), for i = {1, · · · , N}).
3. For mixing parameter π, if ui < π, subject response was Xi, else Ui.
A.10 Algorithm 3: NM Response Data.
Simulation of response data following a mixture of two normal random variables, N1 ∼ N(µ1, σ21)
and N2 ∼ N(µ2, σ22), for a treatment difference, δ:
1. Denote control group response data NC such that it is comprised of N1C ∼ N(µ1C , σ21C) and
N2C ∼ N(µ2C , σ22C), and treatment group response data as NT such that it is comprised of
N1T ∼ N(µ1T , σ21T ) and N2T ∼ N(µ2T , σ22T ).
2. Set control group mean parameters, µ1C and µ2C . Set all SD for equal, σ1T = σ2T = σ1C =
σ2C . And, set the mixing parameter π = 0.5.
3. Find control group mean and variance:
E(NC) = π µ1C + (1− π) µ2C ,




1C) + (1− π) (σ22C + µ22C), and,
V ar(NC) = E(N
2
C)− E(NC)2.
4. Set V ar(NT ) = V ar(NC).
5. Solve for E(NT ) using (2.31).
6. Set ε = 0.5× (µ2C − µ1C).
7. Then, µ1T = E(NT ) − ε and µ2T = E(NT ) + ε.
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A.11 Derivation of Normal MLEs













, y ∈ R,
Consider yi, i = 1, · · · , n, an independent random sample from a normal distribution. The loglike-
lihood of µ and σ given the observed data is maximized to obtain the MLEs for µ and σ, ȳ and s,















Taking the logarithm gives:


























With this, for observed continuous response data Yg (g = {T,C}), the treatment-specific estimates
of the mean and standard deviation are:
{µ̂g, σ̂g} = {ȳg, sg},
when response data follow the normal distribution.
A.12 Derivation of Gamma MLEs





, y ∈ R+, 0 otherwise.
For yi, i = 1, · · · , n, an independent gamma-distributed random sample, the MLEs for α and β,
α̂ and β̂, respectively, are obtained by maximizing the loglikelihood of the parameters given the







and the loglikelihood is:
log`(α, β|y) = n(α− 1)log(y)− n
β
ȳ − nlogΓ(α)− nαlog(β).





while ∂∂α log`(α, β|y) = 0 gives the equation:







where α̂ and β̂ are solved numerically. With this, for observed continuous response data Yg (g =
{T,C}), the treatment-specific estimates of the mean and standard deviation are:
{µ̂g, σ̂g} = {α̂gβ̂g, α̂gβ̂2g},
when response data follow a gamma distribution.
A.13 Derivation of χ2-Uniform Mixture MLEs
Let X ∼ χ2k and U ∼ U(a, b) (k, a, b ∈ R+) where E(X) = k and V ar(X) = 2k and E(U) =
a+b
2 and
V ar(U) = (b−a)
2
12 and X ⊥ U . Now take Y = πX + (1− π)U for mixing parameter π (π ∈ (0, 1)).
Then,
E(Y ) = πE(X) + (1− π)E(U)




V ar(Y ) = π2V ar(X) + (1− π)2V ar(U) + 2π(1− π)Cov(X,U)
= π22k + (1− π)2 (b− a)
2
12











For a random sample yi, (i = 1, · · · , n), estimates of the parameters characterizing the χ2-Uniform
mixture distribution, i.e., θ = (π, k, a, b), given by θ̂, are obtained through the maximization of the
likelihood. Where Y has the PDF:
fY (y) = πfX(x|k) + (1− π)fU (u|a, b), (15)
for x ∈ R+ and u ∈ R (0, otherwise), the corresponding likelihood is given by:



















(1− π)fU (ui|a, b)
]
.




















































































equal to zero gives â = min(ui) and b̂ = max(ui). Finally, for π̂, take p to be a Bernoulli random
variable with probability parameter π such that:
p =

1 with probability π, if yi ∼ χ2k,
0 with probability 1− π, if yi ∼ U(a, b).







(1− π)fU (u|a, b)
]1−p
,











(1− π)fU (ui|a, b)
]1−pi
,





pilog(πfX(xi|k)) + (1− pi)log((1− π)fU (ui|a, b))
}
,

















equal to zero gives π̂ = q/n. From this, group-specific estimates of the mean and standard deviations
of the χ2-Uniform mixture distribution based upon the observed continuous response data Yg (g =
{T,C}) are:

















A.14 Derivation of Normal-Mixture MLEs
Let Xj ∼ N(µj , σ2j ) for j = 1, 2 where E(Xj) = µj (µj ∈ R) and V ar(Xj) = σ2j (σj ∈ R+) and
X1 ⊥ X2. Now let Y = αX1 + (1− α)X2 for mixing parameter α (α ∈ (0, 1)). Then,
E(Y ) = αE(X1) + (1− α)E(X2)
= αµ1 + (1− α)µ2,
and,
V ar(Y ) = α2V ar(X1) + (1− α)2V ar(X2) + 2α(1− α)Cov(X1, X2)
= α2σ21 + (1− α)2σ22, because X1 ⊥ X2





For a random sample yi, (i = 1, · · · , n), estimates of the parameters characterizing the mixture of




2), given by θ̂, are obtained through the maximization























, xj ∈ R; 0, otherwise,
(17)









































, when yi ∼ fX2 .
Setting log`(µ1, σ
2
1|y) and log`(µ2, σ22|y) equal to zero gives the MLEs µ̂j and σ̂2j derived in Ap-
pendix A.11. For the derivation of α̂, take p to be a Bernoulli random variable with probability
137
parameter α, i.e., p ∼ Bern(α), such that:
p =

1 with probability α, if yi ∼ fX1 ,
0 with probability 1− α, if yi ∼ fX2 .


















































setting equal to zero gives α̂ =
∑n
i=1 pi/n. From this, treatment-specific estimates of the mean
and standard deviation of the NM distribution based upon observed continuous response data
Yg (g = {T,C}) are:
µ̂g = α̂gµ̂1g + (1− α̂g)µ̂2g
σ̂g = {α̂g(σ̂21g + σ̂22g) + σ̂22g(1− 2α̂g)}1/2.
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A.15 Lead-in Analysis Results for Continuous Response Data
Table A.15: Observed percent of successful trials over increasing LPGs for HEFT ran-
domization of Normal and Gamma response data and mixture randomization of mixture-
distributed response data.
%̂success for HEFT RAR %̂success for HEFT RAR
when Truth = Normal when Truth = Gamma
LPG δ = 0.0 δ = 0.2 δ = 0.5 δ = 0.8 δ = 0.0 δ = 0.2 δ = 0.5 δ = 0.8
3 68.9 71.5 73.2 75.8 71.8 76.1 77.0 77.6
4 65.7 65.6 70.0 74.7 69.7 70.8 72.7 77.1
5 63.3 62.7 68.3 72.1 64.6 67.3 70.2 76.0
6 61.0 61.3 67.2 70.9 62.6 67.6 70.3 74.7
7 62.3 66.5 66.8 69.9 69.8 69.4 73.3 74.9
8 64.7 68.5 70.4 75.4 71.9 73.6 74.4 74.7
9 64.0 64.3 68.7 75.7 70.1 72.2 75.9 79.9
10 64.1 65.0 69.9 77.2 69.7 69.6 75.7 79.8
11 61.8 64.7 69.9 80.3 65.7 68.4 72.5 78.3
12 64.5 64.5 71.7 80.4 68.1 65.5 73.8 80.2
13 65.7 67.8 70.9 83.3 64.0 67.7 74.3 82.8
14 72.3 70.3 77.3 83.5 66.3 66.9 83.0 86.4
15 80.6 81.5 80.4 86.1 77.1 76.3 84.9 89.5
16 89.3 89.7 91.3 91.9 89.7 91.6 92.4 91.7
17 88.1 88.7 90.8 89.3 88.7 88.1 89.0 93.8
18 91.5 91.5 93.1 92.5 93.7 93.8 94.5 93.5
19 90.1 90.1 91.1 91.8 93.3 100.0 100.0 100.0
20 90.7 92.4 93.4 92.4 92.5 93.1 93.1 92.0
%̂success for X2U RAR %̂success for NM RAR
when Truth = X2U when Truth = NM
LPG δ = 0.0 δ = 0.2 δ = 0.5 δ = 0.8 δ = 0.0 δ = 0.2 δ = 0.5 δ = 0.8
3 35.4 39.1 41.9 43.9 0.3 1.2 0.9 1.3
4 57.8 60.5 62.5 64.9 16.8 17.3 15.7 15.1
5 72.7 72.2 74.9 78.5 41.4 41.7 40.7 38.0
6 81.7 82.5 84.3 85.4 60.0 62.3 62.4 62.0
7 88.8 88.1 89.1 91.6 76.7 77.9 74.6 77.1
8 94.1 92.5 94.3 95.1 86.7 86.3 85.9 86.2
9 94.5 93.5 96.1 96.1 92.2 93.2 92.1 91.3
10 95.9 95.7 97.2 98.1 96.1 95.4 96.7 96.9
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A.16 Randomization results when Truth=Normal and δ = 0.2
Figure A.16: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials when the normality
assumption was true and a small treatment difference existed.
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A.17 Randomization results when Truth=Normal and δ = 0.5
Figure A.17: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials when the normality
assumption was true and a moderate treatment difference existed.
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A.18 Randomization results when Truth=Gamma and δ = 0.2
Figure A.18: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the gamma distribution and reflected a small difference.
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A.19 Randomization results when Truth=Gamma and δ = 0.5
Figure A.19: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the gamma distribution and reflected a moderate difference.
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A.20 Randomization results when Truth=X2U and δ = 0.2
Figure A.20: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the X2U distribution and reflected a small difference.
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A.21 Randomization results when Truth=X2U and δ = 0.5
Figure A.21: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the X2U distribution and reflected a moderate difference.
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A.22 Randomization results when Truth=NM and δ = 0.2
Figure A.22: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the NM distribution and reflected a small difference.
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A.23 Randomization results when Truth=NM and δ = 0.5
Figure A.23: Mean of RAR ratios with 95% CI (A) and percent-difference between the observed
and expected ethical objective function (B) over 1,000 simulated trials where group-specific
subject responses followed the NM distribution and reflected a moderate difference.
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A.24 Derivation of Laplace MLEs













(a− y)I{y<a} + (y − a)I{y≥a}
])
, y ∈ R, 0 otherwise.
For yi, i = 1, · · · , n, an independent Laplace-distributed random sample, the MLEs for a and b,
â and b̂, respectively, are obtained by maximizing the loglikelihood of the parameters given the










(a− yi)I{yi<a} + (yi − a)I{yi≥a}
])
,
and the loglikelihood is:










i=1(a− yi), if yi < a,
−nlog(2b)− 1/b
∑n
i=1(yi − a), if yi ≥ a.







i=1(a− yi), if yi < a,
−1/b
∑n
i=1(yi − a), if yi ≥ a.
Setting ∂∂a log`(a, b|y) = 0 gives:
0 = ∂∂a
∑n
i=1(a− yi), if yi < a,
0 = ∂∂a
∑n
i=1(yi − a), if yi ≥ a.
148












i=1 |yi − a|
b2
.








solved numerically. With this, for observed continuous response data Yg (g = {T,C}) following a
Laplace distribution, the treatment-specific estimates of the mean and standard deviation are:
{µ̂g, σ̂g} = {âg, b̂g
√
2}.
A.25 Derivation of Logistic MLEs












)]2 , y ∈ R+, 0 otherwise.
For yi (i = 1, · · · , n), an independent logistic-distributed random sample, the MLEs of a and b,
given as â and b̂, respectively, are obtained my maximizing the loglikelihood of the parameters



















− yi − a
b









To find â and b̂, respectively, ∂∂a log`(a, b|y) and
∂
∂b log`(a, b|y) are:
∂
∂a





















1 + exp(−yi−ab )
)]
.
Then, setting ∂∂a log`(a, b|y) and
∂
∂b log`(a, b|y) equal to zero gives the following equations to be


























With this, for observed continuous response data Yg (g = {T,C}), the group-specific estimates of
the mean and SD are:
{µ̂g, σ̂g} = {âg, b̂gπ/
√
3},
when responses follow the logistic distribution.
A.26 Derivation of Weibull MLEs (Continuous)












, y ∈ R+, 0 otherwise.
For yi, i = 1, · · · , n, an independent Weibull-distributed random sample, the MLEs for α and β,
α̂ and β̂, respectively, are obtained by maximizing the loglikelihood of the parameters given the















and the loglikelihood is:

































where α̂ and β̂ are solved numerically. With this, for observed continuous response data Yg (g =
{T,C}) following a Weibull distribution, the treatment-specific estimates of the mean and standard
deviation are:















A.27 Derivation of Lognormal MLEs (Continuous)















, y ∈ R+, 0 otherwise.
For yi, (i = 1, · · · , n), an independent lognormally-distributed random sample, the MLEs of a and
b, given as â and b̂, respectively, are obtained my maximizing the loglikelihood of the parameters











































To find â and b̂, respectively, ∂∂a log`(a, b|y) and
∂
∂b log`(a, b|y) are:
∂
∂a
















{log(yi)− a}2 − n
]
.
Then, setting ∂∂a log`(a, b|y) and
∂
















With this, for observed continuous response data Yg, (g = {T,C}), the group-specific estimates of













when responses follow the lognormal distribution.
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A.28 Chapter 2 Simulated Trial R Code
library(polspline)
library(pracma)













mu.A0 <- mu.B0 - 0.8*sigma.0
mu.A1 <- mu.B0 - delta*sigma.0
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## 1. lead-in function -- block randomization
ld.in <- function(){
A.dat <- rnorm(lpg*2, mean=mu.A1, sd=sigma.0)
B.dat <- rnorm(lpg*2, mean=mu.B0, sd=sigma.0)
resp <- c(A.dat[1:lpg], B.dat[(lpg+1):(lpg*2)])
grp <- c(rep(’A’, lpg), rep(’B’, lpg))
rho.hat <- 0.5
U <- runif(lpg*2) ## just to fill these in bc don’t feel like having ’NA’
df00 <- cbind.data.frame(A.dat, B.dat, U, rho.hat, grp, resp)
lead <- nrow(df00)
xbar.A <- xbar.B <- NULL





s.A <- s.B <- rep(NA, lead)




n.A <- n.B <- NULL




df0 <- cbind.data.frame(df00, xbar.A, xbar.B, s.A, s.B, n.A, n.B)
df.NA <- as.data.frame(matrix(NA, nrow=N-lead, ncol=ncol(df0)))
colnames(df.NA) <- colnames(df0)
df <- as.data.frame(rbind(df0, df.NA))
df$A.dat[(lead+1):N] <- rnorm(N-lead, mean=mu.A1, sd=sigma.0)





## 2. randomization process
rand <- function(mean.A, sd.A, mean.B, sd.B, cc=0.01){
psi.A <- mean.A^(tau/2)
psi.B <- mean.B^(tau/2)
rho.obs <- (sd.A * psi.B) / ((sd.A * psi.B) + (sd.B * psi.A))
rho.hat <- ifelse(psi.A > 0 & psi.B > 0 & rho.obs < cc,
cc,
ifelse(psi.A > 0 & psi.B > 0 & cc <= rho.obs & rho.obs <= 1-cc,
rho.obs,
ifelse(psi.A > 0 & psi.B > 0 & rho.obs > 1-cc,
1-cc,
ifelse(psi.A > 0 & psi.B < 0,
cc,
ifelse(psi.A < 0 & psi.B > 0,
1-cc,
ifelse(psi.A < 0 & psi.B < 0












intv <- seq(0, max(dat), length.out = inf.sub)
heft.Ft <- try(pheft(q=intv, fit=hft.fit), silent=T)
if(is(heft.Ft, "try-error")){





area <- area2 <- NULL
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for (i in 1:(inf.sub-1)) {
xt1 <- c(intv[i], intv[i+1])
area[i] <- trapz(x = xt1, y = c(y1[i], y1[i+1]))
area2[i] <- trapz(x = xt1, y = c(y2[i], y2[i+1]))
}
ex.heft <- sum(area)







rh <- Gp <- Obs <- N.A <- N.B <- matrix(NA, ncol=n.trials, nrow=N)
SD.A <- SD.B <- Mean.A <- Mean.B <- matrix(NA, ncol=n.trials, nrow=N)
for (j in 1:n.trials) {
ld <- ld.in()
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## completing the trial data-frame for remaining N-lead subjects
for (i in (ld$lead+1):N) {
A.df <- subset(ld$df, grp=="A")$A.dat










ld$df$rho.hat[i] <- rand(mean.A=A.heft$ex.heft, sd.A=A.heft$sd.heft,
mean.B=B.heft$ex.heft, sd.B=B.heft$sd.heft)
ld$df$grp[i] <- with(ld$df, ifelse(U[i] < rho.hat[i], "A", "B"))
ld$df$resp[i] <- with(ld$df, ifelse(grp[i]=="A", A.dat[i], B.dat[i]))
ld$df$n.A[i] <- sum(ld$df$grp[1:i]==’A’, na.rm=T)




















A.29 Chapter 3 Simulated Trial R Code
library(stats4)








































## 1. lead-in function true data
ld.in <- function(){
A.dat <- rnorm(lpg*2, mean=mu.A1, sd=sigma.0)
B.dat <- rnorm(lpg*2, mean=mu.B0, sd=sigma.0)
df00 <- cbind.data.frame(A.dat, B.dat)
eval(parse(text=paste0(paste0(’df00$grp.k’, k.mat, sep=’ <- ’, collapse=’’),
"df00$grp.wa <- c(rep(’A’, lpg), rep(’B’, lpg))",
sep=’’, collapse=’’)))
eval(parse(text=paste0(paste0(’df00$resp.k’, k.mat, sep=’ <- ’, collapse=’’),
"df00$resp.wa <- c(A.dat[1:lpg], B.dat[(lpg+1):(lpg*2)])",
sep=’’, collapse=’’)))




xbar.A <- xbar.B <- NULL




s.A <- s.B <- rep(NA, lead)




n.A <- n.B <- NULL




eval(parse(text=paste0(’df00$xbar.’, c(’A’, ’B’), ’.wa <- xbar.’, c(’A’, ’B’), sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’df00$s.’, c(’A’, ’B’), ’.wa <- s.’, c(’A’, ’B’), sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’df00$n.’, c(’A’, ’B’), ’.wa <- n.’, c(’A’, ’B’), sep=’’, collapse=’; ’)))
grd2 <- cbind.data.frame(gp=c(rep(’A’, K), rep(’B’, K)), nm=rep(k.mat, 2))
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eval(parse(text=paste0(’df00$xbar.’, grd2$gp, ’.k’, grd2$nm, ’ <- xbar.’, grd2$gp, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’df00$s.’, grd2$gp, ’.k’, grd2$nm, ’ <- s.’, grd2$gp, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’df00$n.’, grd2$gp, ’.k’, grd2$nm, ’ <- n.’, grd2$gp, sep=’’, collapse=’; ’)))
df.NA <- as.data.frame(matrix(NA, nrow=N-lead, ncol=ncol(df00)))
colnames(df.NA) <- colnames(df00)
df <- as.data.frame(rbind(df00, df.NA))
df$A.dat[(lead+1):N] <- rnorm(N-lead, mean=mu.A1, sd=sigma.0)
df$B.dat[(lead+1):N] <- rnorm(N-lead, mean=mu.B0, sd=sigma.0)
df$U.wa[(lead+1):N] <- runif(length((lead+1):N))
eval(parse(text=paste0(’df$U.k’, k.mat, ’[(lead+1):N] <- runif(N-lead)’)))
df$d.0 <- c(rep(0, lead), rep(NA, N-lead))
eval(parse(text=paste0(paste0(’df$rho.hat.k’, k.mat, sep=’’, collapse=’ <- ’),
’ <- c(rep(0.5, lead), rep(NA, N-lead))’)))
eval(parse(text=paste0(paste0(’df$d.k’, k.mat, sep=’’, collapse=’ <- ’), ’ <- ’,
paste0(’df$d.k’, k.mat, ’.star’, sep=’’, collapse=’ <- ’),
’ <- d.0 <- c(rep(0, lead), rep(NA, N-lead))’)))
eval(parse(text=paste0(’df$w.numr.k’, k.mat, ’ <- exp(-0.5*df$d.k’, k.mat, ’.star)’, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’df$w.den <- with(df, ’,
paste0(’w.numr.k’, k.mat, sep=’’, collapse=’ + ’), ’)’)))
eval(parse(text=paste0(’df$w.k’, k.mat, ’ <- with(df, w.numr.k’, k.mat, ’/w.den)’, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’df$rho.hat.wa <- with(df, ’,
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## 6. randomization process
rand <- function(mean.A, sd.A, mean.B, sd.B, cc=0.01){
psi.A <- mean.A^(tau/2)
psi.B <- mean.B^(tau/2)
rho.obs <- (sd.A * psi.B) / ((sd.A * psi.B) + (sd.B * psi.A))
rho.hat <- ifelse(psi.A > 0 & psi.B > 0 & rho.obs < cc,
cc,
ifelse(psi.A > 0 & psi.B > 0 & cc <= rho.obs & rho.obs <= 1-cc,
rho.obs,
ifelse(psi.A > 0 & psi.B > 0 & rho.obs > 1-cc,
1-cc,
ifelse(psi.A > 0 & psi.B < 0,
cc,
ifelse(psi.A < 0 & psi.B > 0,
1-cc,
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#### 7. gamma MLE function (k=1)
gam.mle.fn <- function(grp.dat, start.alpha, start.beta){
logL.gam <- function(alpha, beta) {
-sum(suppressWarnings(dgamma(grp.dat, shape=alpha, scale=beta, log=T)))
}
mle.gam1 <- try(mle(minuslogl = logL.gam,
start = list(alpha=start.alpha, beta=start.beta),
method = "L-BFGS-B",
lower = rep(1e-05, 2), upper=rep(10^5, 2)), silent=T); #mle.gam1
if(is(mle.gam1, "try-error")){












#### 8. normal MLE function (k2)
norm.mle.fn <- function(grp.dat, start.mu, start.sigma) {
logL.norm <- function(mu, sigma){
-sum(dnorm(grp.dat, mean=mu, sd=sigma, log=T))
}
mle.norm <- try(mle(minuslogl = logL.norm,
start = list(mu = start.mu, sigma = start.sigma),
method = "L-BFGS-B",
lower = c(-10^5, 1e-05), upper=c(10^5, 10^5)), silent=T)
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if(is(mle.norm, "try-error")){














#### 9. logistic MLE function (k2)
logis.mle.fn <- function(grp.dat, start.loc, start.sc){
logL.logis <- function(loc, sc){
























mle.lap.sd <- sqrt(2) * b.hat








Rh.wa <- Obs.wa <- Grp.wa <- Unf.wa <- matrix(NA, ncol=n.trials, nrow=N)
Min.MOF <- Wt.denr <- matrix(NA, ncol=n.trials, nrow=N)
N.A.wa <- N.B.wa <- Mean.A.wa <- Mean.B.wa <- SD.A.wa <- SD.B.wa <- matrix(NA, ncol=n.trials, nrow=N)
eval(parse(text=paste0(paste0(’Rh.k’, k.mat,
’ <- MOF.k’, k.mat, ’ <- MOF.star.k’, k.mat,
’ <- Wt.numr.k’, k.mat, ’ <- Weight.k’, k.mat,
’ <- Obs.k’, k.mat, ’ <- Unf.k’, k.mat,
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’ <- N.A.k’, k.mat, ’ <- N.B.k’, k.mat,
’ <- SD.A.k’, k.mat, ’ <- SD.B.k’, k.mat,
’ <- Mean.A.k’, k.mat, ’ <- Mean.B.k’, k.mat,
sep=’’, collapse=’ <- ’),
’ <- matrix(NA, ncol=n.trials, nrow=N)’)))
for (j in 1:n.trials) {
#### normal randomization (k=1)
ld <- ld.in()
for (i in (ld$lead+1):N) {
A.df <- subset(ld$df, grp.wa=="A")$A.dat
B.df <- subset(ld$df, grp.wa=="B")$B.dat
##### for normal rho-hat (k=4) #####
norm.mle.A <- norm.mle.fn(grp.dat=A.df, start.mu=mu.A1, start.sigma=sigma.0)
norm.mle.B <- norm.mle.fn(grp.dat=B.df, start.mu=mu.B0, start.sigma=sigma.0)
if(is.na(norm.mle.A$mle.norm.mean) | is.na(norm.mle.A$mle.norm.sd) |




ld$df$rho.hat.k4[i] <- rand(mean.A = norm.mle.A[[1]], sd.A = norm.mle.A[[2]],





ld$df$grp.k4[i] <- with(ld$df, ifelse(U.k4[i] < rho.hat.k4[i], "A", "B"))
ld$df$resp.k4[i] <- with(ld$df, ifelse(grp.k4[i]=="A", A.dat[i], B.dat[i]))
ld$df$n.A.k4[i] <- sum(ld$df$grp.k4[1:i]==’A’, na.rm=T)
ld$df$n.B.k4[i] <- sum(ld$df$grp.k4[1:i]==’B’, na.rm=T)
}
ld$df$d.k4[i] <- norm.mle.fn(grp.dat=ld$df$resp.wa[1:(i-1)], start.mu=(mu.A1+mu.B0)/2,
start.sigma=sigma.0)[[3]]
##### for gamma rho-hat (k=3) #####
gam.mle.A <- gam.mle.fn(grp.dat=A.df, start.alpha=alpha.A1, start.beta=beta.A1)
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gam.mle.B <- gam.mle.fn(grp.dat=B.df, start.alpha=alpha.B0, start.beta=beta.B0)
if(is.na(gam.mle.A$mle.gam.mean) | is.na(gam.mle.A$mle.gam.sd) |
is.na(gam.mle.B$mle.gam.mean) | is.na(gam.mle.B$mle.gam.sd)) {
break
} else {






ld$df$grp.k3[i] <- with(ld$df, ifelse(U.k3[i] < rho.hat.k3[i], "A", "B"))
ld$df$resp.k3[i] <- with(ld$df, ifelse(grp.k3[i]=="A", A.dat[i], B.dat[i]))
ld$df$n.A.k3[i] <- sum(ld$df$grp.k3[1:i]==’A’, na.rm=T)






##### for logistic rho-hat (k=2) #####
logis.mle.A <- logis.mle.fn(grp.dat=A.df, start.loc=mu.A1, start.sc=strt.scl.logis)
logis.mle.B <- logis.mle.fn(grp.dat=B.df, start.loc=mu.B0, start.sc=strt.scl.logis)
if(is.na(logis.mle.A$mle.logis.mean) | is.na(logis.mle.A$mle.logis.sd) |
is.na(logis.mle.B$mle.logis.mean) | is.na(logis.mle.B$mle.logis.sd)) {
break
} else {
ld$df$rho.hat.k2[i] <- rand(mean.A = logis.mle.A[[1]], sd.A = logis.mle.A[[2]],





ld$df$grp.k2[i] <- with(ld$df, ifelse(U.k2[i] < rho.hat.k2[i], "A", "B"))
ld$df$resp.k2[i] <- with(ld$df, ifelse(grp.k2[i]=="A", A.dat[i], B.dat[i]))
ld$df$n.A.k2[i] <- sum(ld$df$grp.k2[1:i]==’A’, na.rm=T)
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##### for laplace rho-hat (k=2) #####
lap.mle.A <- lap.mle.fn(grp.dat=A.df)
lap.mle.B <- lap.mle.fn(grp.dat=B.df)




ld$df$rho.hat.k1[i] <- rand(mean.A = lap.mle.A[[1]], sd.A = lap.mle.A[[2]],






ld$df$grp.k1[i] <- with(ld$df, ifelse(U.k1[i] < rho.hat.k1[i], "A", "B"))
ld$df$resp.k1[i] <- with(ld$df, ifelse(grp.k1[i]=="A", A.dat[i], B.dat[i]))
ld$df$n.A.k1[i] <- sum(ld$df$grp.k1[1:i]==’A’, na.rm=T)
ld$df$n.B.k1[i] <- sum(ld$df$grp.k1[1:i]==’B’, na.rm=T)
}
ld$df$d.k1[i] <- lap.mle.fn(grp.dat=ld$df$resp.wa[1:(i-1)])[[3]]
##### developing weights #####
eval(parse(text=paste0(’ld$df$d.0[i] <- min(’, paste0(’ld$df$d.k’, k.mat, ’[i]’,
sep=’’, collapse=’, ’), ’, na.rm=T)’)))
eval(parse(text=paste0(’ld$df$d.k’, k.mat, ’.star[i] <- with(ld$df, d.k’, k.mat,
’[i]-d.0[i])’, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’ld$df$w.numr.k’, k.mat, ’[i] <- exp(-0.5*ld$df$d.k’, k.mat,
’.star[i])’, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’ld$df$w.den[i] <- with(ld$df, ’,
paste0(’w.numr.k’, k.mat, ’[i]’, sep=’’, collapse=’ + ’), ’)’)))
eval(parse(text=paste0(’ld$df$w.k’, k.mat, ’[i] <- with(ld$df, w.numr.k’, k.mat,
’[i]/w.den[i])’, sep=’’, collapse=’; ’)))
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##### weighted-average randomization #####
eval(parse(text=paste0(’ld$df$rho.hat.wa[i] <- with(ld$df, ’,
paste0(’rho.hat.k’, k.mat, ’[i]*w.k’, k.mat, ’[i]’,





ld$df$grp.wa[i] <- with(ld$df, ifelse(U.wa[i]<rho.hat.wa[i], ’A’, ’B’))
ld$df$resp.wa[i] <- with(ld$df, ifelse(grp.wa[i]==’A’, A.dat[i], B.dat[i]))
ld$df$n.A.wa[i] <- sum(ld$df$grp.wa[1:i]==’A’, na.rm=T)















eval(parse(text=paste0(’Rh.k’, k.mat, ’[,j] <- ld$df$rho.hat.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’Unf.k’, k.mat, ’[,j] <- ld$df$U.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’Obs.k’, k.mat, ’[,j] <- ld$df$resp.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’MOF.k’, k.mat, ’[,j] <- ld$df$d.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’MOF.star.k’, k.mat, ’[,j] <- ld$df$d.k’, k.mat, ’.star’, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’Wt.numr.k’, k.mat, ’[,j] <- ld$df$w.numr.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’Weight.k’, k.mat, ’[,j] <- ld$df$w.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’N.A.k’, k.mat, ’[,j] <- ld$df$n.A.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’N.B.k’, k.mat, ’[,j] <- ld$df$n.B.k’, k.mat, sep=’’, collapse=’; ’)))
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eval(parse(text=paste0(’SD.A.k’, k.mat, ’[,j] <- ld$df$s.A.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’SD.B.k’, k.mat, ’[,j] <- ld$df$s.B.k’, k.mat, sep=’’, collapse=’; ’)))
eval(parse(text=paste0(’Mean.A.k’, k.mat, ’[,j] <- ld$df$xbar.A.k’, k.mat, sep=’’, collapse=’; ’)))










type1 <- ’E’ ## data: exp
type2 <- ’NA’ ## RAR: nelson-aalen cumulative hazard
hr.sz <- ’L’ ## large HR








R <- 85 /rcu.pd ### recruitment period (85 days) / 85
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D <- 100 /rcu.pd ### trial duration (100 days) / 85
days <- 30 /rcu.pd ### interested in 30-day survival / 85
### ^^^ idk if 30/85 is really looking at 30 days
#=================================================================================================
grp.labb <- c(’C’,’T’)
vrrs <- c(’tm.g’, ’ldin’, ’grp’, ’A0’, ’C0’, ’C1’, ’S0’, ’S1’, ’Z0’)
pwr.vrs.df <- c("z.stat", "pval", "rej", "HR.obs.NA", ’HR.obs.exp’)
pwr.vrs.est <- c(’zz.stat’, ’pvalu’, ’rejj’, ’hr.obs.na’, ’hr.obs.exp’)
#=================================================================================================
## 1. censoring function
xi.fn <- function(thta, DD, RR){
1 - thta/DD + exp(-DD/thta) * (thta/(DD*RR)) * (exp(RR/thta) * (2*thta-RR) - 2*thta)
}
#=================================================================================================
### to select control group parameters
tht.vec <- seq(from=15.9, to=16.1, by=0.00001) /rcu.pd
xi.thtv <- xi.fn(tht.vec, D, R)
xi.C.df0 <- data.frame(tht.vec, xi.thtv, bias=xi.thtv-(1-pct/100))
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### setting control group parms
tht.C1.init <- xi.C.df0$tht.vec[which.min(abs(xi.C.df0$bias))]
xi.C1.init <- xi.fn(tht.C1.init, D, R)
haz.C1.init <- 1/tht.C1.init
sd.tht.C1 <- tht.C1.init/sqrt(xi.C1.init)
### treatment group parameters
haz.T1.init <- haz.C1.init/HR.1
tht.T1.init <- 1/haz.T1.init




## 2. survival randomization process






rho.obs <- tt1 / (tt1 + tt2)
rho.hat <- ifelse(psi.T > 0 & psi.C > 0 & rho.obs < cc,
cc,
ifelse(psi.T > 0 & psi.C > 0 & cc <= rho.obs & rho.obs <= 1-cc,
rho.obs,
ifelse(psi.T > 0 & psi.C > 0 & rho.obs > 1-cc,
1-cc,
ifelse(psi.T > 0 & psi.C < 0,
cc,
ifelse(psi.T < 0 & psi.C > 0,
1-cc,
ifelse(psi.T < 0 & psi.C < 0








## 3. deriving arrival & censoring data for both groups
# step 1: generating arrival and censoring data
# for both groups st arrival times < censor time
# and adding 50/50 C/T group variable for PBD(1) lead-in
ac.dat <- function(){
A0 <- sort(runif(N*2, 0, R)) ## U(0,1) arrival times
C0 <- runif(N*2, 0, D)
C1 <- C0+A0
grp <- rep(grp.labb, N)





## 4. prepping the Z1/W0/T0 matrices
byt.df <- function(df01.spl, matr, clnm.txt){
dff <- as.data.frame(matr)
clnms <- paste0(’c(’, paste0("’", clnm.txt, ".t", 1:(nrow(df01.spl)-1), "’", sep=’’, collapse=’, ’),
", ’", clnm.txt, ".D’)", sep=’’, collapse=’’)
colnames(dff) <- eval(parse(text=clnms))






## 5. deriving survival times
# step 2: splitting data by group to pull grp-specific survival time
# st survival times > its corresponding arrival time
df.split <- function(df01, grp.lab, grp.tht){
df01.gp <- subset(df01, grp==grp.lab)
df01.gp$S0 <- rexp(nrow(df01.gp), rate=1/grp.tht)
df01.gp$S1 <- with(df01.gp, S0+A0)
df01.gp$Z0 <- with(df01.gp, pmin(S1, C1, D))
df01.spl <- df01.gp #rbind.data.frame(df01.gp, c(D, rep(NA, ncol(df01.gp)-1)))
df01.spl$tm.g <- 1:nrow(df01.spl)
Z1.mat <- W0.mat <- matrix(NA, nrow=nrow(df01.spl)-1, ncol=nrow(df01.spl))
Cnt.mat <- T0.mat <- matrix(NA, nrow=nrow(df01.spl)-1, ncol=nrow(df01.spl))
for(n. in 2:nrow(df01.spl)){
cnt0 <- with(df01.spl, 1*(A0[n.]>=Z0[1:(n.-1)]))
z1 <- with(df01.spl, ifelse(A0[n.]<Z0[1:(n.-1)], A0[n.], Z0[1:(n.-1)]))
w0 <- with(df01.spl, 1*(z1==S1[1:(n.-1)]))
t0 <- with(df01.spl, z1-A0[1:(n.-1)])
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Cnt.mat[,n.] <- c(cnt0, rep(NA, nrow(df01.spl)-n.))
Z1.mat[,n.] <- c(z1, rep(NA, nrow(df01.spl)-n.))
W0.mat[,n.] <- c(w0, rep(NA, nrow(df01.spl)-n.))
T0.mat[,n.] <- c(t0, rep(NA, nrow(df01.spl)-n.))
}
Cnt.mat[1,1] <- Z1.mat[1,1] <- W0.mat[1,1] <- T0.mat[1,1] <- 0
Cntt <- byt.df(df01.spl, Cnt.mat, ’cnt’)
Cnt.df <- Cntt$dff
df01.spl$cnt <- Cntt$col.sums
ZZ1 <- byt.df(df01.spl, Z1.mat, ’Z1’)
Z1.df <- ZZ1$dff
WW0 <- byt.df(df01.spl, W0.mat, ’W0’)
W0.df <- WW0$dff
df01.spl$W0.sums <- WW0$col.sums
TT0 <- byt.df(df01.spl, T0.mat, ’T0’)
T0.df <- TT0$dff
# step 5: creating indicator for number of observed outcomes












# step 6: df.split function above to generate full group-specific data
dfspl.C <- df.split(df01, ’C’, tht.C1.init)
dfspl.T <- df.split(df01, ’T’, tht.T1.init)
df01.C <- dfspl.C$df01.spl
df01.T <- dfspl.T$df01.spl




ld.sz.gp <- max(ld.sz.C, ld.sz.T)
# step 8: pulling the group-specific lead-in data (df02.g)
# step 9: ensuring at least one event in each lead-in group (resulting data: df02.chk.g)
# else, re-run until true (hence repeat loop) [shouldn’t be a problem most of the time]
tmp2 <- paste0(’df01.’, grp.labb, ’$ldin <- 0; ’,
’df01.’, grp.labb, ’$ldin[df01.’, grp.labb, ’$tm.g %in% 1:ld.sz.gp] <- 1; ’,
’df02.’, grp.labb, ’ <- df01.’, grp.labb, ’[which(df01.’, grp.labb, ’$ldin==1),]; ’,
’df02.chk.’, grp.labb, ’ <- df02.’, grp.labb, ’[with(df02.’, grp.labb,






eval(parse(text=paste0(’Cnt.df.’, grp.labb, ’ <- dfspl.’, grp.labb, ’$Cnt.df; ’,
’Z1.df.’, grp.labb, ’ <- dfspl.’, grp.labb, ’$Z1.df; ’,
’W0.df.’, grp.labb, ’ <- dfspl.’, grp.labb, ’$W0.df; ’,
’T0.df.’, grp.labb, ’ <- dfspl.’, grp.labb, ’$T0.df’)))
df01.C$ldin00 <- df01.T$ldin00 <- NULL
df01.C$cnt <- df01.T$cnt <- NULL
df01.C$W0.sums <- df01.T$W0.sums <- NULL
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df02 <- rbind.data.frame(df01.C, df01.T)
df03 <- df02[order(df02$A0),]
df04 <- df03[which(df03$ldin==1),]
df04.NA <- as.data.frame(matrix(NA, nrow=N-nrow(df04), ncol=ncol(df04)))
colnames(df04.NA) <- colnames(df04)
df05 <- rbind.data.frame(df04, df04.NA)
df05b <- df05[vrrs]
df06a <- cbind.data.frame(tm=1:nrow(df05), df05b)
df06a$rho.hat <- ifelse(df06a$ldin==1, 0.5, NA)





haz.T <- haz.C <- n.T <- n.C <- xii.T <- xii.C <- rep(NA, nrow(df06a))
z.stat <- pval <- rej <- HR.obs.NA <- HR.obs.exp <- rep(NA, nrow(df06a))
tht.T <- tht.C <- sd.tht.T <- sd.tht.C <- rep(NA, nrow(df06a))
z1.sum.C <- w0.sum.C <- t0.sum.C <- z1.sum.T <- w0.sum.T <- t0.sum.T <- rep(NA, nrow(df06a))
Ht.exp.C <- Ht.exp.T <- Ht.NA.C <- Ht.NA.T <- se.Ht.NA.C <- se.Ht.NA.T <- rep(NA, nrow(df06a))
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tmp3 <- data.frame(z1.sum.C, w0.sum.C, t0.sum.C, z1.sum.T, w0.sum.T, t0.sum.T,
tht.T, tht.C, xii.T, xii.C, haz.T, haz.C, sd.tht.T, sd.tht.C,
n.T, n.C, z.stat, pval, rej, HR.obs.NA, HR.obs.exp,
Ht.exp.C, Ht.exp.T, Ht.NA.C, Ht.NA.T, se.Ht.NA.C, se.Ht.NA.T)
df06 <- cbind.data.frame(df06a, tmp3)
return(list(ld.sz.C=ld.sz.C, ld.sz.T=ld.sz.T, ld.sz.gp=ld.sz.gp,






Z1.C <- with(df03, ifelse(A0[nrow(df03)]<Z0[1:(nrow(df03)-1)], A0[nrow(df03)], Z0[1:(nrow(df03)-1)]))
W0.C <- with(df03, 1*(Z1.C==S1[1:(nrow(df03)-1)]))
T0.C <- with(df03, Z1.C-A0[1:(nrow(df03)-1)])
cdf0 <- cbind.data.frame(Z1.C, W0.C, T0.C)




fitKM.C1 <- survfit(Surv(T0.C, W0.C) ~ 1)
tm.untl1 <- sum(fitKM.C1$time<days)
sum(da.C); sum(tm.untl1)
ht.NA.fit.C1 <- with(fitKM.C1, n.event/n.risk)
Ht.NA.fit.C1 <- cumsum(ht.NA.fit.C1)
var.Ht.NA.fit.C1 <- cumsum(with(fitKM.C1, n.event/n.risk^2))
v.Ht.NA.fit.C1 <- var.Ht.NA.fit.C1*length(T0.C)
se.Ht.NA.fit.C1 <- sqrt(v.Ht.NA.fit.C1)


















ht.NA.fit.C2 <- with(fitKM.C2, n.event/n.risk)
Ht.NA.fit.C2 <- cumsum(ht.NA.fit.C2)
var.Ht.NA.fit.C2 <- cumsum(with(fitKM.C2, n.event/n.risk^2))
v.Ht.NA.fit.C2 <- var.Ht.NA.fit.C2*length(Z1.C)
se.Ht.NA.fit.C2 <- sqrt(v.Ht.NA.fit.C2)

















Rh <- Gp <- Uf <- Tm.Grp <- matrix(NA, ncol=n.trials, nrow=N)
N.T <- N.C <- Xi.T <- Xi.C <- matrix(NA, ncol=n.trials, nrow=N)
HR.Obs.NA <- HR.Obs.Exp <- matrix(NA, ncol=n.trials, nrow=N)
Z.Stat <- Pval <- Rej <- matrix(NA, ncol=n.trials, nrow=N)
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Haz.T <- Haz.C <- Tht.T <- Tht.C <- SD.Tht.T <- SD.Tht.C <- matrix(NA, ncol=n.trials, nrow=N)
A0.obs <- C0.Obs <- C1.Obs <- S0.Obs <- S1.Obs <- Z0.Obs <- matrix(NA, ncol=n.trials, nrow=N)
Z1.Sums.C <- W0.Sums.C <- T0.Sums.C <- matrix(NA, ncol=n.trials, nrow=N)
Z1.Sums.T <- W0.Sums.T <- T0.Sums.T <- matrix(NA, ncol=n.trials, nrow=N)
lead.vec <- ld.C.vec <- ld.T.vec <- rep(NA, n.trials)
CumHaz.NA.C <- CumHaz.NA.T <- CumHaz.Exp.C <- CumHaz.Exp.T <- matrix(NA, ncol=n.trials, nrow=N)





















###### control data and MLE estimation
C.df.06 <- df06[which(df06$grp==’C’), vrrs]
C.df.03 <- df03[with(df03, which(grp==’C’ & tm.g==tm.grp)), vrrs]
C.df.0 <- rbind.data.frame(C.df.06, C.df.03)
Z1.C <- with(C.df.0, ifelse(A0[nrow(C.df.0)]<Z0[1:(nrow(C.df.0)-1)],
A0[nrow(C.df.0)], Z0[1:(nrow(C.df.0)-1)]))
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W0.C <- with(C.df.0, 1*(Z1.C==S1[1:(nrow(C.df.0)-1)]))
T0.C <- with(C.df.0, Z1.C-A0[1:(nrow(C.df.0)-1)])
da.C <- 1*(Z1.C<days)
tht.C <- sum(T0.C)/sum(W0.C)
xii.C <- xi.fn(tht.C, D, R)
haz.C <- 1/tht.C
sd.tht.C <- tht.C/sqrt(xii.C)
fitKM.C <- survfit(Surv(T0.C, W0.C) ~ 1)
tm.untl <- sum(fitKM.C$time<days)
ht.NA.fit.C <- with(fitKM.C, n.event/n.risk)
Ht.NA.fit.C <- cumsum(ht.NA.fit.C)#/length(T0.C)
# var.Ht.NA.fit.C <- cumsum(with(fitKM.C, ((n.risk-n.event)/(n.risk-1))*(n.event/n.risk^2)))















# plot(x=haz.C.df$time, y=haz.C.df$Ht.NA.fit.C, type=’S’)
# abline(v=days, lty=2, col=’darkgrey’)
# abline(h=haz.C.df[tm.untl,3], lty=2, col=’darkgrey’)
###### trt data and MLE estimation
T.df.06 <- df06[which(df06$grp==’T’), vrrs]
T.df.03 <- df03[with(df03, which(grp==’T’ & tm.g==tm.grp)), vrrs]
T.df.0 <- rbind.data.frame(T.df.06, T.df.03)
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Z1.T <- with(T.df.0, ifelse(A0[nrow(T.df.0)]<Z0[1:(nrow(T.df.0)-1)],
A0[nrow(T.df.0)], Z0[1:(nrow(T.df.0)-1)]))
W0.T <- with(T.df.0, 1*(Z1.T==S1[1:(nrow(T.df.0)-1)]))
T0.T <- with(T.df.0, Z1.T-A0[1:(nrow(T.df.0)-1)])
tht.T <- sum(T0.T)/sum(W0.T)
xii.T <- xi.fn(tht.T, D, R)
haz.T <- 1/tht.T
sd.tht.T <- tht.T/sqrt(xii.T)
fitKM.T <- survfit(Surv(T0.T, W0.T) ~ 1)
tm.untl.T <- sum(fitKM.T$time<days)
ht.NA.fit.T <- with(fitKM.T, n.event/n.risk)
Ht.NA.fit.T <- cumsum(ht.NA.fit.T)
var.Ht.NA.fit.T <- cumsum(with(fitKM.T, n.event/n.risk^2))
v.Ht.NA.fit.T <- var.Ht.NA.fit.T*length(T0.T)
se.Ht.NA.fit.T <- sqrt(v.Ht.NA.fit.T)











###### putting estimated parms into overall data frame matrix
tmp5 <- paste0(’df06$tht.’, grp.labb, ’[tm.i-1] <- tht.’, grp.labb, ’; ’,
’df06$xii.’, grp.labb, ’[tm.i-1] <- xii.’, grp.labb, ’; ’,
’df06$haz.’, grp.labb, ’[tm.i-1] <- haz.’, grp.labb, ’; ’,
’df06$sd.tht.’, grp.labb, ’[tm.i-1] <- sd.tht.’, grp.labb, ’; ’,
’df06$n.’, grp.labb, ’[tm.i-1] <- nrow(’, grp.labb, ’.df.06); ’,
’df06$z1.sum.’, grp.labb, ’[tm.i-1] <- sum(Z1.’, grp.labb, ’); ’,
’df06$w0.sum.’, grp.labb, ’[tm.i-1] <- sum(W0.’, grp.labb, ’); ’,
’df06$t0.sum.’, grp.labb, ’[tm.i-1] <- sum(T0.’, grp.labb, ’)’)
eval(parse(text=tmp5))
eval(parse(text=paste0(’df06$Ht.NA.’, grp.labb, ’[tm.i-1] <- Ht.NA.’, grp.labb, ’; ’,
’df06$se.Ht.NA.’, grp.labb, ’[tm.i-1] <- se.Ht.NA.’, grp.labb, ’; ’,
’df06$Ht.exp.’, grp.labb, ’[tm.i-1] <- Ht.exp.’, grp.labb)))
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###### randomization
df06$rho.hat[tm.i] <- with(df06[tm.i-1,], rand(Ht.NA.T, Ht.NA.C, se.Ht.NA.T, se.Ht.NA.C))






eval(parse(text=paste0(’df06$’, vrrs, ’[tm.i] <- df.add$’, vrrs)))
###### testing for power
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